

10565979.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
enhanced  
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:34:16 ON 08 DEC 2008

=> ....Testing the current file.... screen

10565979.trn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Please change to a suitable file and repeat your upload

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

FILE 'REGISTRY' ENTERED AT 10:34:43 ON 08 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d l1

NO L# DEFINED

There are no L# queries, structures, or screen sets defined in the current session.


=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\10565979-res.str

10565979.trn



```
chain nodes :
7 14 15
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
16 17
chain bonds :
6-7 7-8 11-14 14-15 15-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
6-7 7-8 11-12 11-14 14-15 15-16 15-17
exact bonds :
8-9 8-13 9-10 10-11 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 8 :
```

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS
```

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

10565979.trn

L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:35:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5629 TO ITERATE

35.5% PROCESSED 2000 ITERATIONS

6 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 108081 TO 117079


PROJECTED ANSWERS: 91 TO 583

L3 6 SEA SSS SAM L1

=> d scan

10565979.trn


L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-5-quinolinyl-  
MF C23 H25 Cl N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):200

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(phenylamino)-  
MF C27 H30 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidinebutanamide, N,N-dimethyl-4-[(1-oxopropyl)phenylamino]-  
α,α-diphenyl-  
MF C32 H39 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-(4-phenoxyphenyl)-  
MF C27 H31 N3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


10565979.trn

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidineacetamide,  
N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)-  
3-methoxyphenyl]amino]-  
MF C23 H31 N3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1-Piperidineacetamide,  
4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-[4-(1-  
hydroxyethyl)phenyl]-  
MF C22 H28 F N3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10565979.trn

=> s l1 full  
FULL SEARCH INITIATED 10:35:58 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 112731 TO ITERATE

100.0% PROCESSED 112731 ITERATIONS 519 ANSWERS  
SEARCH TIME: 00.00.03

L4 519 SEA SSS FUL L1

=> file caplus  
FILE 'CAPLUS' ENTERED AT 10:36:05 ON 08 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2008 VOL 149 ISS 24  
FILE LAST UPDATED: 7 Dec 2008 (20081207/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l4  
L5 27 L4

=> d cbib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 27 ANSWERS - CONTINUE? Y/(N):y

GT




AB This invention relates to compds. of formula I for the inhibition of histone deacetylase. More particularly, the invention provides for compds. of formula compds. of the formula I and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixts., diastereomers and enantiomers thereof. Compds. of formula I wherein M is alkyl, NHOH and derivs., CF<sub>3</sub>, COOH and derivs., C<sub>2</sub>H<sub>5</sub>, OH, COCH<sub>3</sub>, H, and derivs., and wherein X is CH<sub>3</sub>, C(OH), C-Cl-4-alkyl, C-halo, C-(hetero)aryl, etc.; L and Y are independently Cl-4 alkyl, heteroaryl, alkenyl, alkynyl, NN2 and derivs., OH and derivs., etc.; and N-oxides, solvates, pharmaceutically acceptable salts, prodrugs, complexes, racemic mixts., scalemic mixture, diastereomers, and enantiomers thereof, are claimed. Example compound II was prepared by

methylation of diphenylacetic acid followed by amidation with hydroxylamine. All the invention compds. were evaluated for their HDAC inhibitory activity. From the assay, it was determined that compound II exhibited IC60 value of  $\leq 1 \mu\text{M}$ .

IT 1070701-69-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

15 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS ON STN  
2008:551640 Document No. 148:059953 Preparation of phenylpropionamide  
compounds for treating disorders responsive to activation of opioid  
receptors. Zhou, Xiaoming (Purdue Pharma L.P., USA). PCT Int. Appl. WO  
2008:03352 AB, 2008:0508, 53pp. DESIGNATED STATES: W, AE, AG, AI, AM, AT,  
AU, AZ, B3, BE, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,  
DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GM, GR, GT, HN, HU, IL, IN,  
LU, IL, LN, LS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LI, LR, LS, LT,  
LU, LY, MA, MD, ME, MG, MK, MN, MM, KP, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TZ, TM,  
TN, TR, TT, TZ; RW: AT, BE, BF, BG, CF, CG, CI, CM, CY, DE, DK, ES,  
FI, FR, GA, GB, GE, IE, IS, IT, LU, MC, MR, MT, NE, NL, PE, SE, SN,  
TG, TH, TN, TD (BENIN) PAKISTAN. PUBLICATION: WO 2007-1B3411  
200711031. PRIORITY: US 2006-855826P 20061101.

GI



AB The invention relates to phenylpropionamide compds. of Formula I and pharmaceutically acceptable salts, prodrgs, and solvates thereof, wherein

A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; B is (CH<sub>2</sub>)<sub>m</sub> wherein m is 0-12; R1 is H, halo, Cl-6-alkyl, etc.; R2 is Cl-6-alkyl, C2-6-alkenyl, etc.; R3 and R4 are independently cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and R5 is H, CN, Cl-6-alkyl, etc.

The invention is also directed to the use of compds. of Formula I to treat, prevent, ameliorate a disorder responsive to the action of opiod receptors, particularly  $\mu$ -opiod receptors. Compds. of the present invention are especially useful for treating pain. Synthesis of


present invention are especially useful for treating pain. Synthesis of the compounds of the present invention is exemplified. Example compound II was prepared by reacting 3-cyano-3,3-diphenylpropylbromide with N-[piperidin-4-yl]-N-phenylpropionamide. In a  $\mu$ -opioid receptor binding assay, II had a  $K_i$  of 82.83 nM.

IT 1021954-04-OP, N,N-Dimethyl-2,2-diphenyl-4-[4-([N-phenyl-N-(propionyl)amino]piperidin-1-yl)butanamide 1021954-05-1P, N-[1-(4-Oxo-3,3-diphenyl-4-(oxycarbonyl)-1-yl)butyl]piperidin-4-yl-N-

L5 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
(drug candidate; prepn. of N-hydroxy carboxamide derivs. as histone  
deacetylase inhibitors useful in the treatment of HDAC-mediated  
diseases)

RN 1070701-69-7 CAPLUS

CN 1-Piperidineacetamide, N-hydroxy-4-[(1-oxopropyl)phenylamino]- $\alpha$ -  
phenyl- (CA INDEX NAME)




L5 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
phenylpropionamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


```

      (uses)
      (drug candidate; prepn. of phenylpropionamide compds. for use in
      treating diseases responsive to opioid receptor activation)
RN  1021954-04-0  CAPLUS
CN  1-Piperidinebutanamide, N,N-dimethyl-4-[(1-oxopropyl)phenylamino]-
      - $\alpha$ , $\alpha$ -diphenyl-  (CA INDEX NAME)

```



RN 1021954-05-1 CAPLUS  
CN Propanamide, N-[1-[4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl]-4-piperidinyl]-N-phenyl- (CA INDEX NAME)





10565979.trn

L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2008:548314 Document No. 148:538082 Preparation of phenylamino-substituted piperidine compounds as NPY5 receptor regulators. Garcia-Lopez, Monica; Mas-Prio, Josep; Torrens-Jover, Antonio (Laboratorios Del Dr. Esteve

S.A., Spain). PCT Int. Appl. WO 2008052769 A1 20080508, 90pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-EP9465 20071031. PRIORITY: EP 2006-384017 20061102.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X, Y = H, halo, nitro, etc.; R1-R3 = H, halo, aliphatic radical, etc.; R5 = H, aliphatic radical or -A-CO-NR1OR11; R6-R9 = H, aliphatic radical, cyano, etc.; A = -CHR18 or -CHR18-CH2-; R10 = H or aliphatic radical; R11 = aliphatic radical, cycloaliph. radical, aryl radical, etc.;


R18 = H or aliphatic radical] or stereoisomers (preferably enantiomers or diastereomers), racemates, mixts. of at least two of stereoisomers (preferably enantiomers or diastereomers, in any mixing ratio), salts (preferably physiol. acceptable salts), or solvates thereof were prepared Thus, a multi-step synthesis of compound II [R = OH; Z = -CO-], starting from 3-aminofluoren-9-one, was given. In Neuropeptide Y5 (NPY5) binding assays, the IC50 value of compound II [R = H; Z = -N(Et)-] (III) was 23.7 nM. Compds. I are claimed useful for the treatment of obesity, anorexia, etc. Pharmaceutical composition comprising compound III is disclosed.

IT 1023288-73-4P 1023288-74-5P 1023288-75-6P  
 1023288-76-7P 1023288-77-8P 1023288-78-9P  
 1023288-79-0P 1023288-80-3P 1023288-81-4P  
 1023288-82-5P 1023288-83-6P 1023288-84-7P  
 1023288-85-8P 1023288-86-9P 1023288-87-0P  
 1023288-88-1P 1023288-89-2P 1023288-90-5P  
 1023288-91-6P 1023288-92-7P 1023288-93-8P  
 1023288-94-9P 1023288-95-0P 1023288-96-1P  
 1023288-97-2P 1023288-98-3P 1023288-99-4P  
 1023289-00-0P 1023289-01-1P 1023289-02-2P  
 1023289-03-3P 1023289-04-4P 1023289-05-5P  
 1023289-06-6P 1023289-07-7P 1023289-08-8P  
 1023289-09-9P 1023289-10-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylamino-substituted piperidine compds. as NPY5 receptor regulators)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 1023288-73-4 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(2-hydroxyphenyl)amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 1023288-74-5 CAPLUS  
 CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[(2-hydroxyphenyl)amino]- (CA INDEX NAME)



RN 1023288-75-6 CAPLUS  
 CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-hydroxyphenyl)amino]- (CA INDEX NAME)




RN 1023288-76-7 CAPLUS  
 CN 1-Piperidineacetamide, N-(4-cyclohexylphenyl)-4-[(2-hydroxyphenyl)amino]- (CA INDEX NAME)




RN 1023288-77-8 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(2-hydroxyphenyl)amino]-N-6-quinolinyl- (CA INDEX NAME)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-78-9 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(2-hydroxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



RN 1023288-79-0 CAPLUS  
 CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(2-hydroxyphenyl)amino]- (CA INDEX NAME)




RN 1023288-80-3 CAPLUS  
 CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[(2-hydroxyphenyl)amino]- (CA INDEX NAME)




RN 1023288-81-4 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(2-hydroxyphenyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-82-5 CAPLUS  
 CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(3-hydroxyphenyl)amino]- (CA INDEX NAME)



RN 1023288-83-6 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(3-hydroxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 1023288-84-7 CAPLUS  
 CN 1-Piperidineacetamide, N-[4-[ethyl(2-hydroxyethyl)amino]phenyl]-4-[(3-hydroxyphenyl)amino]- (CA INDEX NAME)




RN 1023288-85-8 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(3-hydroxyphenyl)amino]-N-6-quinolinyl- (CA INDEX NAME)

10565979.trn


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-86-9 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(3-hydroxyphenyl)amino]-  
(CA INDEX NAME)



RN 1023288-87-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(4-hydroxyphenyl)amino]-  
(CA INDEX NAME)




RN 1023288-88-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-hydroxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)-  
(CA INDEX NAME)




RN 1023288-89-2 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-methoxyphenyl)amino]-  
(CA INDEX NAME)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-94-9 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[(2-methoxyphenyl)amino]-  
(CA INDEX NAME)



RN 1023288-95-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(3-methoxyphenyl)amino]-  
(CA INDEX NAME)




RN 1023288-96-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[(3-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)-  
(CA INDEX NAME)




RN 1023288-97-2 CAPLUS  
CN 1-Piperidineacetamide, N-[4-[ethyl(2-hydroxyethyl)amino]phenyl]-4-[(3-methoxyphenyl)amino]-  
(CA INDEX NAME)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-90-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)-  
(CA INDEX NAME)



RN 1023288-91-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)amino]-N-6-quinolinyl-  
(CA INDEX NAME)




RN 1023288-92-7 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(2-methoxyphenyl)amino]-  
(CA INDEX NAME)




RN 1023288-93-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)amino]-N-3-quinolinyl-  
(CA INDEX NAME)


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023288-98-3 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[(3-methoxyphenyl)amino]-  
(CA INDEX NAME)



RN 1023288-99-4 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(4-methoxyphenyl)amino]-  
(CA INDEX NAME)




RN 1023289-00-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)-  
(CA INDEX NAME)




RN 1023289-01-1 CAPLUS  
CN 1-Piperidineacetamide, N-[4-[ethyl(2-hydroxyethyl)amino]phenyl]-4-[(4-methoxyphenyl)amino]-  
(CA INDEX NAME)

10565979.trn


L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023289-02-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-methoxyphenyl)amino]-N-(4-phenoxyphe-nyl)- (CA INDEX NAME)



RN 1023289-03-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-methoxyphenyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 1023289-04-4 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-(phenylamino)- (CA INDEX NAME)




RN 1023289-05-5 CAPLUS  
CN 1-Piperidineacetamide, N-(9-oxo-9H-fluoren-3-yl)-4-(phenylamino)- (CA INDEX NAME)

L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023289-10-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-hydroxyphenyl)[2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




L5 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 1023289-06-6 CAPLUS  
CN 1-Piperidineacetamide, N-[4-[ethyl(2-hydroxyethyl)amino]phenyl]-4-(phenylamino)- (CA INDEX NAME)



RN 1023289-07-7 CAPLUS  
CN 1-Piperidineacetamide, 4-(phenylamino)-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)



RN 1023289-08-8 CAPLUS  
CN 1-Piperidineacetamide, N-(4-phenoxyphe-nyl)-4-(phenylamino)- (CA INDEX NAME)



RN 1023289-09-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-oxo-2-[(4-phenoxyphe-nyl)amino]ethyl]phenylamino]-N-(4-phenoxyphe-nyl)- (CA INDEX NAME)


L5 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

2007:1138519 Document No. 148:55361 Development of Novel Enkephalin Analogues that Have Enhanced Opioid Activities at Both  $\mu$  and  $\delta$  Opioid Receptors. Lee, Yeon Sun; Petrov, Ravil; Park, Chad K.; Ma, Shou-wu; Davis, Peg; Lai, Josephine; Porreca, Frank; Vardanyan, Ruben; Hruby, Victor J. (Departments of Chemistry and Pharmacology, University of Arizona, Tucson, AZ, 85721, USA). Journal of Medicinal Chemistry, 50(22), 5528-5532 (English) 2007. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 148:55361. Publisher: American Chemical Society. AB Enkephalin analogs with a 4-anilidopiperidine scaffold have been designed and synthesized to achieve therapeutic benefit for the treatment of pain due to mixed  $\mu$  and  $\delta$  opioid agonist activities. Ligand H-Dmt-D-Ala-Gly-Phe-Q, in which a Dmt-substituted enkephalin-like structure was linked to the N-phenyl-N-piperidin-4-yl propionamide moiety (Q), showed very high binding affinities (0.4 nM) at  $\mu$  and  $\delta$  receptors with an increased hydrophobicity (aLogPd = 2.96). This novel lead compound was found to have very potent agonist activities in MVD (1.8 nM) and GPI (8.5 nM) assays.


IT 959785-88-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of enkephalin anilidopiperidine analogs having enhanced opioid activities at both  $\mu$  and  $\delta$  opioid receptors)  
RN 959785-88-7 CAPLUS  
CN L-Phenylalanine, L-tyrosyl-D-alanylglycyl-, 2-[1,4-dioxo-4-[4-[(1-oxopropyl)phenylamino]-1-piperidinyl]butyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



10565979.trn



L5 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

2007:731161 Document No. 147:143472 Preparation of amide inhibitors of leukotriene A4 hydrolase for treating inflammatory disorders. Chen, Ming;

Claret, Emmanuel; Cleve, Arwed; Davey, David; Guilford, William; Khim, Seock-Kyu; Kirkland, Thomas; Kochanny, Monica J.; Liang, Amy; Light, David; Parkinson, John; Vogel, David; Wei, Guo Ping; Ye, Bin; Ye, Hong (Schering Aktiengesellschaft, Germany). U.S. Pat. Appl. Publ. US 20070155727 A1 20070705, 107pp. (English). CODEN: USXXCO. APPLICATION: US 2006-644822 20061222. PRIORITY: US 2005-755732P 20051229; US 2006-835483P 20060804.

GI



AB This invention is directed to compds. of formula (I) (where  $x = 0-4$ ;  $q = 0-2$ ; R = (un)substituted benzyl, (un)substituted heteroaryl, etc.; R2 is H, alkyl, haloalkyl, etc., or forms part of a heterocyclic ring; R3 is a direct bond, -O-, (un)substituted straight or branched alkylene chain, etc.; R4a, R4b and R4c are independently a direct bond, (un)substituted straight or branched alkylene chain, etc.; each R5a, R5b, R5c, R6a, R6b and R6c is independently H, alkyl, haloalkyl, etc., or in some cases form part of a cycloalkyl ring; R7 is H, alkyl, haloalkyl, etc., or forms part of a heterocyclic ring; R8 is H, alkyl, haloalkyl, haloalkenyl, (un)substituted aralkyl; each R9 is independently alkyl, hydroxyalkyl, halo, aryl, etc.; each R10 is independently H, alkyl, haloalkyl, etc.)

are

described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compns. comprising the compds. of the invention and methods of using and preparing the compds.

of

the invention are also disclosed. Example compound II was prepared by reacting hexahydro-N-(4-phenoxyphenyl)-1H-1,4-diazepine-1-acetamide with Me 4-isocyanatobenzoate. Compds. of the invention, when tested in the LTA4 hydrolase homogeneous time resolved fluorescence assay, demonstrated the ability to inhibit LTA4 hydrolase activity at IC50 values of less

than


L5 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

100  $\mu$ M, preferably at less than 1  $\mu$ M.  
IT 943785-82-8P, Methyl 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(amide inhibitors of leukotriene A4 hydrolase for treating inflammatory disorders and other diseases)

RN 943785-82-8 CAPLUS

CN Benzoic acid, 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]-, methyl ester (CA INDEX NAME)




IT 943785-83-9P, 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoic acid 943789-29-5P, 4-[Methyl 1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoic acid 943789-30-8P, 3-Methyl-4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoic acid 943789-31-9P, 2-Methyl-4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; amide inhibitors of leukotriene A4 hydrolase for treating inflammatory disorders and other diseases)


RN 943785-83-9 CAPLUS

CN Benzoic acid, 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]- (CA INDEX NAME)



RN 943789-29-5 CAPLUS


CN Benzoic acid, 4-[methyl 1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]- (CA INDEX NAME)



RN 943789-30-8 CAPLUS


L5 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN Benzoic acid, 3-methyl-4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]- (CA INDEX NAME)




RN 943789-31-9 CAPLUS

CN Benzoic acid, 2-methyl-4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]- (CA INDEX NAME)



10565979.trn


L5 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2006:101557 Document No. 144:171021 Preparation of piperazine and related  
 N-hydroxy succinic acid diamide derivatives as metalloproteinase  
 inhibitors with therapeutic uses. Swinnen, Dominique; Bombrun, Agnes;  
 Gonzalez, Jerome; Crosignani, Stefano; Gerber, Patrick; Jorand-Lebrun,  
 Catherine (Applied Research Systems Ars Holding N.V., Neth. Antilles).  
 PCT Int. Appl. WO 2006010751 A1 20060202, 203 pp. DESIGNATED STATES: W:  
 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO,  
 CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI,  
 CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE,  
 NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO  
 2005-EP53616 20050725. PRIORITY: EP 2004-103574 20040726; US  
 2004-591111P 20040726; EP 2005-100641 20050131; US 2005-648924P 20050201.  
 GI



AB The present invention is related to piperazine and related N-hydroxy  
 succinic acid diamide derivs. (shown as I; variables defined below; e.g.  
 (2S,3S)-N-hydroxy-2-hydroxy-5-methyl-3-[[4-(2-pyridinyl)-1-  
 piperazinyl]carbonyl]hexanamide (shown as II)) and use thereof, in  
 particular for the treatment and/or prophylaxis of autoimmune disorders,  
 inflammatory diseases, cardiovascular diseases, neurodegenerative  
 diseases, cancer, respiratory diseases and fibrosis, including multiple  
 sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease,  
 liver and pulmonary fibrosis. A = -C(B)- and N; B is H or B forms a bond  
 with either R5 or R7; R' = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,  
 C3-C8-cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C3-C8-cycloalkyl  
 C1-C6 alkyl, heterocycloalkyl C1-C6 alkyl, heteroaryl C1-C6 alkyl, amino  
 and alkoxy; R2 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,


L5 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 874647-07-1 CAPLUS  
 CN 1-Piperidinebutanamide,  $\beta$ -[3-(4-ethoxyphenyl)propyl]-N, $\alpha$ -  
 dihydroxy-4-[[3-(methoxyphenyl)amino]- $\gamma$ -oxo-, ( $\alpha$ S, $\beta$ R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 874647-09-3 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[[3-(dimethylamino)phenyl]amino]- $\beta$ -[3-(4-  
 ethoxyphenyl)propyl]-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, ( $\alpha$ S, $\beta$ R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 874647-13-9 CAPLUS  
 CN 1-Piperidinebutanamide,  $\beta$ -[3-(4-ethoxyphenyl)propyl]-N, $\alpha$ -  
 dihydroxy-4-[[4-hydroxyphenyl]amino]- $\gamma$ -oxo-, ( $\alpha$ S, $\beta$ R)-  
 (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 C3-C8-cycloalkyl, heterocycloalkyl, alkoxy, aryl and heteroaryl; R3 = H,  
 C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl; R4, R5, R6 and R7 = H,  
 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; or R4 and R7 form together a -CH2-  
 linkage; n is an integer = 1, 2, 3, 4, 5 and 6; Carbons (2) and (3) are  
 two chiral centers, wherein chiral center (2) has a configuration = S and  
 R and wherein chiral center (3) has a S configuration as well as  
 pharmaceutically acceptable salts thereof. Methods of prepn. are claimed  
 and preps. and/or characterization data for .apprx.90 examples of I are  
 included. For example, II was prepd. from a 55/45 mixt. of (2S)- and  
 (2R)-pentafluorophenyl 2-((4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)-4-  
 methylpentanoate (prepn. by partial diastereoisomerization of latter  
 isomer) by 1st creating an amide linkage using 1-(2-pyridyl)piperazine  
 (40 %) and then a 2nd amide linkage using hydroxylamine (31 %). IC50 values  
 for inhibition of MMP-1, MMP-2, MMP-9 and MMP-12 by 16 examples of I are  
 tabulated. Also, percentage of inhibition of IL-2-induced peritoneal  
 recruitment of lymphocytes (model for cellular migration that occurs  
 during inflammation) by 8 examples of I are tabulated.  
 IT 874646-81-8P, (2S,3R)-3-[(4-Anilinopiperidin-1-yl)carbonyl]-6-(4-  
 ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874647-07-1P,  
 (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[[3-  
 methoxyphenyl]amino]piperidin-1-yl]carbonyl]hexanamide  
 874647-09-3P, (2S,3R)-3-[[4-[[3-  
 (Dimethylamino)phenyl]amino]piperidin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-  
 hydroxy-2-hydroxyhexanamide 874647-13-9P,  
 (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[[4-  
 hydroxyphenyl]amino]piperidin-1-yl]carbonyl]hexanamide  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of piperazine and related N-hydroxy  
 succinic acid diamide derivs. as metalloproteinase inhibitors with therapeutic  
 uses)  
 RN 874646-81-8 CAPLUS  
 CN 1-Piperidinebutanamide,  $\beta$ -[3-(4-ethoxyphenyl)propyl]-N, $\alpha$ -  
 dihydroxy- $\gamma$ -oxo-4-(phenylamino)-, ( $\alpha$ S, $\beta$ R)- (CA INDEX  
 NAME)

Absolute stereochemistry.




L5 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2006:75104 Document No. 144:170886 Preparation of dimeric compounds of  
 piperidine, piperazine or morpholine or their 7-membered analogs suitable  
 for the treatment of neurodegenerative disorders. Clk, Miroslav; Diels,  
 Gaston Stanislas Marcel; Van Lommen, Guy Rosalia Eugene (Janssen  
 Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2006008259 A1 20060126, 51  
 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
 BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,  
 FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG,  
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT,  
 BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE,  
 IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English).  
 CODEN: PIXXD2. APPLICATION: WO 2005-EP53345 20050713. PRIORITY: US  
 2004-588446P 20040716; EP 2004-103413 20040716.  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [n = 1 or 2; m = 0-3; Z = CH, CH2, N, or O; X =  
 (un)substituted alkynyl, alkyl, etc.; R1 and R2 independently = H, alkyl,  
 alkylcarbonyl, heterocycle, etc.; or R1 and R2 taken together form a  
 (un)substituted heterocycle; R3 independently = H or alkoxy], the N-oxide  
 forms and the pharmaceutically acceptable addition salts, are prepared  
 and disclosed as suitable for treatment of neurodegenerative disorders.  
 Thus, e.g., II was prepared by deprotection of III (preparation given)  
 followed by reaction with 1,4-dichloro-2-butyne. Neuron viability assays were  
 conducted using calcein-AM, e.g., II was determined to possess a pIC50  
 value from 6-8. Pharmaceutical formulations are claimed.  
 IT 874536-05-7P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of dimeric compds. of piperidine, piperazine or  
 morpholine or their 7-membered analogs suitable for treatment of neurodegenerative  
 disorders)  
 RN 874536-05-7 CAPLUS  
 CN Benzeneacetamide, N,N'-[(1,6-dioxo-1,6-hexanediyl)di-1,4-  
 piperidinediyl]bis[N-(4-chlorophenyl)-4-methyl- (9CI) (CA INDEX NAME)

10565979.trn

L5 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



PAGE 1-B



L5 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2005;636147 Document No. 143;205792 A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists. Dordal, Alberto; Lipkin, Mike; Macritchie, Jackie; Mas, Josep; Port, Adriana; Rose, Sally; Salgado, Leonardo; Savic, Vladimir; Schmidt, Wolfgang; Serafini, Maria Teresa; Spearing, William; Torrens, Antoni; Yeste, Sandra (BioFocus Discovery Limited, Saffron Walden, CB10 1XL, UK). Bioorganic & Medicinal Chemistry Letters, 15(16), 3679-3684 (English) 2005. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier B.V..

AB The metabolic stability of benzoxazinone derivs., a potent series of NPY Y5 antagonists, has been investigated. This study resulted in the identification of the structural moieties prone to metabolic transformations and which strongly influenced the in vitro half-life. This provides opportunities to optimize the structure of this new class

of NPY Y5 antagonists.

IT 845553-61-9 845554-07-6 862197-71-5


862197-73-7 862197-75-9 862197-77-1

862197-81-7 862197-84-0 862197-86-2

RL: BSU (Biological study, unclassified); BIOL (Biological study) (metabolic stability of a series of benzoxazinone derivs. as potent neuropeptide Y5 antagonists)


RN 845553-61-9 CAPLUS

CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)



RN 845554-07-6 CAPLUS


CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 862197-71-5 CAPLUS


CN 1-Piperidineacetamide, N-(4-cyclohexylphenyl)-4-[[2-(formylphenyl)amino]- (CA INDEX NAME)

L5 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 862197-73-7 CAPLUS

CN Benzoic acid, 2-[[1-[2-[[4-(cyclohexylphenyl)amino]-2-oxoethyl]-4-piperidinyl]amino]- (CA INDEX NAME)




RN 862197-75-9 CAPLUS

CN 1-Piperidineacetamide, 4-[[2-(formylphenyl)amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)



RN 862197-77-1 CAPLUS


CN Benzoic acid, 2-[[1-[2-[[4-(hydroxyphenylmethyl)phenyl]amino]-2-oxoethyl]-4-piperidinyl]amino]- (CA INDEX NAME)



RN 862197-81-7 CAPLUS


CN 1-Piperidineacetamide, N-9H-carbazol-3-yl-4-[[2-(formylphenyl)amino]- (CA INDEX NAME)

L5 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 862197-84-0 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(formylphenyl)amino]- (CA INDEX NAME)



RN 862197-86-2 CAPLUS


CN Benzoic acid, 2-[[1-[2-[[9-ethyl-9H-carbazol-3-yl]amino]-2-oxoethyl]-4-piperidinyl]amino]- (CA INDEX NAME)



10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2005:300405 Document No. 142:373687 Preparation of  
 N-substituted-N-(4-piperidinyl) amide derivatives as analgesics.  
 Takahashi, Toshihiro; Endo, Tsuyoshi; Sakuma, Syogo; Mochiduki, Nobutaka;  
 Yamakawa, Tomio; Shika, Kiichi; Kawasaki, Toru; Imai, Toshiyasu; Hirate,  
 Kenji (Nippon Chemiphar Co., Ltd., Japan). PCT Int. Appl. WO 2005030722  
 A1 20050407, 112 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,  
 BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,  
 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
 KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
 ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW:  
 AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR,  
 IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese).  
 CODEN: PIXXD2. APPLICATION: WO 2004-JP14562 20040928. PRIORITY: JP  
 2003-337480 20030929.


GI



AB (4-Acylamino-1-piperidinyl)alkanamide derivs. (I) [R1 = Cl-6 alkyl, 3- to 7-membered cycloalkyl, Cl-6 alkoxy-Cl-6 alkyl, 5- or 6-membered heterocyclyl; R2 = each (un)substituted Ph or 5- or 6-membered heterocyclyl; R3 = H, Ph, C2-8 alkoxy-carbonyl, Cl-6 alkoxy, Me; R4 = (un)substituted Ph; R5 = H, Cl-6 alkyl, Cl-6 alkyl-C6-10 aryl; R6 = H, Cl-6 alkyl, Ph, 5- or 6-membered heterocyclyl, Cl-6 alkyl-C6-10 aryl, heterocyclyl-Cl-6 alkyl; wherein each Cl-6 alkyl, aryl of aryl-Cl-6 alkyl, heterocyclyl or heterocyclyl-Cl-6 alkyl is optionally substituted; R7 = H, Me; m = 1,2] or salts thereof are prepared Also disclosed is an analgesic containing the compds. I or a salt thereof as an active constituent. These compds. possess excellent affinity to opioid  $\mu$  receptor and some of them are selective agonists of peripheral opioid  $\mu$  receptor without central nervous system side effects such as dependency, bradycardia, respiratory suppression, or suppression of digestive tract movement. Thus, 3-[4-methoxycarbonyl-4-(N-phenylpropionylamino)piperidin-1-yl]-2-phenylpropionic acid was amidated with methylamine using 1-hydroxybenzotriazole hydrate and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 to give 1-(2-methylcarbamoyl-2-phenylethyl)-4-(N-phenylpropionylamino)piperidine-4-carboxylic acid Me ester (II) which was converted into the oxalic acid salt. II oxalate inhibited the binding of [3H]DAMGO to human opioid  $\mu$  receptor with IC50 of 8 nM.  
 IT 849474-02-8P 849474-04-0P 849474-06-2P

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CRN 849474-02-8  
 CMF C35 H40 N4 O4



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4



RN 849474-06-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-(3-amino-3-oxo-2-phenylpropyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-08-4 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-(3-amino-3-oxo-2-phenylpropyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1  
 CRN 849474-06-2  
 CMF C25 H31 N3 O4


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

849474-08-4P 849474-09-5P 849474-10-8P  
 849474-11-9P 849474-12-0P 849474-13-1P  
 849474-14-2P 849474-15-3P 849474-16-4P  
 849474-17-5P 849474-18-6P 849474-19-7P  
 849474-20-0P 849474-21-1P 849474-22-2P  
 849474-23-3P 849474-24-4P 849474-25-5P  
 849474-26-6P 849474-27-7P 849474-28-8P  
 849474-29-9P 849474-30-2P 849474-31-3P  
 849474-32-4P 849474-33-5P 849474-34-6P  
 849474-35-7P 849474-36-8P 849474-37-9P  
 849474-38-0P 849474-39-1P 849474-40-4P  
 849474-41-5P 849474-42-6P 849474-43-7P  
 849474-44-8P 849474-45-9P 849474-46-0P  
 849474-47-1P 849474-48-2P 849474-49-3P  
 849474-50-6P 849474-51-7P 849474-52-8P  
 849474-53-9P 849474-54-0P 849474-55-1P  
 849474-56-2P 849474-57-3P 849474-58-4P  
 849474-59-5P 849474-60-8P 849474-61-9P  
 849474-62-0P 849474-63-1P 849474-64-2P  
 849474-65-3P 849474-66-4P 849474-67-5P  
 849474-68-6P 849474-69-7P 849474-70-0P  
 849474-72-2P 849474-74-4P 849474-75-5P  
 849474-77-7P 849474-79-9P 849474-80-2P  
 849474-81-3P 849474-83-5P 849474-84-6P  
 849474-85-7P 849474-86-8P 849474-87-9P  
 849474-88-0P 849474-89-1P 849474-90-4P  
 849474-91-5P 849474-92-6P 849474-93-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-substituted-N-(4-piperidinyl) amide derivs. as opioid  $\mu$  receptor agonists and analgesics)


RN 849474-02-8 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(1H-indol-3-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-04-0 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(1H-indol-3-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4



RN 849474-09-5 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[3-(methylamino)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-10-8 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[3-(methylamino)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1  
 CRN 849474-09-5  
 CMF C26 H33 N3 O4

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-11-9 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-(dimethylamino)-3-oxo-2-phenylpropyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-12-0 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-(dimethylamino)-3-oxo-2-phenylpropyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-11-9  
CMF C27 H35 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-15-3 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-(ethylmethylamino)-3-oxo-2-phenylpropyl]-  
4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-16-4 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-(ethylmethylamino)-3-oxo-2-phenylpropyl]-  
4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-15-3  
CMF C28 H37 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-13-1 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[4-(dimethylamino)-4-oxo-3-phenylbutyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-14-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[4-(dimethylamino)-4-oxo-3-phenylbutyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-13-1  
CMF C28 H37 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-17-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-(phenylamino)propyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-18-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-(phenylamino)propyl]-4-  
[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 849474-17-5  
CMF C31 H35 N3 O4



10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-19-7 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[(phenylmethyl)amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-20-0 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[(phenylmethyl)amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-19-7  
CMF C32 H37 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-21-1 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-22-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-21-1  
CMF C33 H39 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-23-3 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[methyl(2-phenylethyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-24-4 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[methyl(2-phenylethyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-23-3  
CMF C34 H41 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-25-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 4-[(2-furanylcarbonyl)phenylamino]-1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-, methyl ester (CA INDEX NAME)




RN 849474-26-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 4-[(2-furanylcarbonyl)phenylamino]-1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-25-5  
CMF C35 H37 N3 O5

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-27-7 CAPLUS  
CN 1-Piperidinepropanamide, 4-(methoxymethyl)-N-methyl-4-[(1-oxopropyl)phenylamino]- $\alpha$ -phenyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 849474-28-8 CAPLUS  
CN 1-Piperidinepropanamide, 4-(methoxymethyl)-N-methyl-4-[(1-oxopropyl)phenylamino]- $\alpha$ -phenyl-N-(2-phenylethyl)-, ethanediolate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-27-7  
CMF C34 H43 N3 O3

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-31-3 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[methyl(3-phenylpropyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-32-4 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[methyl(3-phenylpropyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-31-3  
CMF C35 H43 N3 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-29-9 CAPLUS  
CN 1-Piperidinepropanamide, N-methyl-4-[(1-oxopropyl)phenylamino]- $\alpha$ ,4-diphenyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 849474-30-2 CAPLUS  
CN 1-Piperidinepropanamide, N-methyl-4-[(1-oxopropyl)phenylamino]- $\alpha$ ,4-diphenyl-N-(2-phenylethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-29-9  
CMF C38 H43 N3 O2

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-33-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[(2-hydroxyethyl)methylamino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-34-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[(2-hydroxyethyl)methylamino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioic acid (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 849474-33-5  
CMF C28 H37 N3 O5

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-35-7 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[(4-amino-4-oxobutyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-36-8 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[(4-amino-4-oxobutyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-35-7  
CMF C29 H38 N4 O5

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-39-1 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-(1-piperidinyl)propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-40-4 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-(1-piperidinyl)propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-39-1  
CMF C30 H39 N3 O4



L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-37-9 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-(4-morpholinyl)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-38-0 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-(4-morpholinyl)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 849474-37-9  
CMF C29 H37 N3 O5

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2  
CRN 144-62-7  
CMF C2 H2 O4




RN 849474-41-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-42-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-41-5  
CMF C31 H40 N4 O5



CM 2


CRN 144-62-7  
CMF C2 H2 O4

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 849474-43-7 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-44-8 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 849474-43-7  
CMP C36 H44 N4 O4



CM 2

CRN 144-62-7  
CMP C2 H2 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CM 2

CRN 144-62-7  
CMP C2 H2 O4




RN 849474-47-1 CAPLUS  
CN D-Glucitol, 1-deoxy-1-[[3-[4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinyl]-1-oxo-2-phenylpropyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849474-48-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-49-3 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 849474-45-9 CAPLUS  
CN D-Glucitol, 1-deoxy-1-[[3-[4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinyl]-1-oxo-2-phenylpropyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 849474-46-0 CAPLUS  
CN D-Glucitol, 1-deoxy-1-[[3-[4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinyl]-1-oxo-2-phenylpropyl]methylamino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 849474-45-9  
CMP C32 H45 N3 O9


Absolute stereochemistry.



L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 849474-48-2

CMP C33 H39 N3 O5




CM 2

CRN 144-62-7  
CMP C2 H2 O4



RN 849474-50-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-pyridinyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-51-7 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-pyridinyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-50-6  
CMP C32 H38 N4 O4

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-52-8 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-thienyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-53-9 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-thienyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-52-8  
CMF C31 H37 N3 O4 S

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-56-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-thienyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-57-3 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-thienyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 849474-56-2  
CMF C30 H37 N5 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-54-0 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(1H-pyrrol-1-yl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-55-1 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(1H-pyrrol-1-yl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-54-0  
CMF C31 H38 N4 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-58-4 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-naphthalenyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-59-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-oxo-2-phenyl-3-[[2-(2-naphthalenyl)ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-58-4  
CMF C37 H41 N3 O4

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-60-8 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-[(1H-indol-2-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)




RN 849474-61-9 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-[(1H-indol-2-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-60-8  
CMF C35 H40 N4 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-64-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-[(1H-indol-3-yl)ethyl]-4-(methoxymethyl)-4-[(1-oxopropyl)phenylamino]-alpha-phenyl-, ethanedioate (1:1) (CA INDEX NAME)



RN 849474-65-3 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-[(1H-indol-3-yl)ethyl]-4-(methoxymethyl)-4-[(1-oxopropyl)phenylamino]-alpha-phenyl-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 849474-64-2  
CMF C35 H42 N4 O3



CM 2

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-62-0 CAPLUS  
CN 4-Piperidinecarboxylic acid, 4-[(2-furanylcarbonyl)phenylamino]-1-[3-[[2-[(1H-indol-3-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-, methyl ester (CA INDEX NAME)



RN 849474-63-1 CAPLUS  
CN 4-Piperidinecarboxylic acid, 4-[(2-furanylcarbonyl)phenylamino]-1-[3-[[2-[(1H-indol-3-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 849474-62-0  
CMF C37 H38 N4 O5

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-66-4 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-[(1H-indol-3-yl)ethyl]-4-[(1-oxopropyl)phenylamino]-alpha,4-diphenyl-, ethanedioate (1:1) (CA INDEX NAME)



RN 849474-67-5 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-[(1H-indol-3-yl)ethyl]-4-[(1-oxopropyl)phenylamino]-alpha,4-diphenyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-66-4  
CMF C39 H42 N4 O2



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 849474-68-6 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-[(1H-indol-3-yl)ethyl]methylamino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)

10565979.trn


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 849474-69-7 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(1H-indol-3-yl)ethyl]methylamino]-3-  
oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester,  
ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-68-6  
CMF C36 H42 N4 O4



CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-70-0 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 1

CRN 849474-73-3  
CMF C34 H40 N4 O2

Relative stereochemistry.




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-75-5 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 849474-77-7 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, ethanedioate (1:1),  
(αR,3S,4S)-rel- (CA INDEX NAME)

CM 1

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 849474-72-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, ethanedioate (1:1),  
(αR,3R,4S)-rel- (CA INDEX NAME)

CM 1

CRN 849474-71-1  
CMF C34 H40 N4 O2

Relative stereochemistry.



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-74-4 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, ethanedioate (1:1),  
(αR,3S,4R)-rel- (CA INDEX NAME)

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 849474-76-6  
CMF C34 H40 N4 O2

Relative stereochemistry.



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-79-9 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(1H-indol-3-yl)ethyl]-3-methyl-4-[(1-  
oxopropyl)phenylamino]-α-phenyl-, ethanedioate (1:1),  
(αR,3R,4R)-rel- (CA INDEX NAME)

CM 1

CRN 849474-78-8  
CMF C34 H40 N4 O2

Relative stereochemistry.



CM 2


CRN 144-62-7

10565979.trn

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CMF C2 H2 O4




RN 849474-80-2 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-oxo-2-phenyl-3-[[2-[4-(phenylmethoxy)-1H-  
indol-3-yl]ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl  
ester (CA INDEX NAME)



RN 849474-81-3 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-oxo-2-phenyl-3-[[2-[4-(phenylmethoxy)-1H-  
indol-3-yl]ethyl]amino]propyl]-4-[(1-oxopropyl)phenylamino]-, methyl  
ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-80-2  
CMF C42 H46 N4 O5



CM 2


CRN 144-62-7  
CMF C2 H2 O4

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 849474-85-7 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(5-hydroxy-1H-indol-3-  
yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-,  
methyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 849474-84-6  
CMF C35 H40 N4 O5




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 849474-86-8 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-  
3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA  
INDEX NAME)



RN 849474-87-9 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-  
3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester,  
ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-86-8  
CMF C36 H42 N4 O4


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 849474-83-5 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(4-hydroxy-1H-indol-3-  
yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-,  
methyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 849474-82-4  
CMF C35 H40 N4 O5




CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 849474-84-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(5-hydroxy-1H-indol-3-  
yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-,  
methyl ester (CA INDEX NAME)



L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-88-0 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(5-chloro-1H-indol-3-yl)ethyl]amino]-  
3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA  
INDEX NAME)



RN 849474-89-1 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(5-chloro-1H-indol-3-yl)ethyl]amino]-  
3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester,  
ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-88-0  
CMF C35 H39 Cl N4 O4





10565979.trn


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-90-4 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(1H-benzimidazol-2-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-91-5 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(1H-benzimidazol-2-yl)ethyl]amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 849474-90-4  
CMF C34 H39 N5 O4



CM 2

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 144-62-7  
CMF C2 H2 O4




RN 849474-92-6 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(benzo[b]thien-3-ylethyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



RN 849474-93-7 CAPLUS  
CN 4-Piperidinecarboxylic acid,  
1-[3-[[2-(benzo[b]thien-3-ylethyl)amino]-3-oxo-2-phenylpropyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 849474-92-6  
CMF C35 H39 N3 O4 S



CM 2

CRN 144-62-7  
CMF C2 H2 O4

L5 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2005:283204 Document No. 142:355173 Preparation of 6-aminoindole and 7-amino-1,2,3,4-tetrahydroquinoline derivatives as non-peptidic neuropeptide Y (NPY) Y2 receptor inhibitors. Cairuthers, Nicholas I.; Chal, Wenyang; Dax, Scott L.; Jablonowski, Jill A.; Li, Xiaobing; Lovenberg, Timothy W.; Murray, William V.; Rudolph, Dale A.; Seierstad, Mark; Youngman, Mark A. (Johnson & Johnson Pharmaceutical Research & Development, LLC, USA). U.S. Pat. Appl. Publ. US 20050070534 A1 20050331, 34 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-949055 20040924. PRIORITY: US 2003-505462P 20030924.  
GI




AB The title compds. (I) [wherein the fused pyrrolidine ring optionally contains a single carbon- carbon double bond or a single carbon ring member adjacent to the nitrogen is optionally :O substituted; n = 1, 2; m = 0,1, 2; Y1 = each C0-5 alkylene, alkenylene, alkynylene, or acylene -CH(CONRfRg)-, -CH(CO2C1-4 alkyl)- (where Rf, Rg = H or C1-4 alkyl); Y2 = H, Ph, C4-8 cycloalkyl, or C4-8 cycloalkenyl, wherein each ring optionally substituted; Y3 = -CH2-, carbonyl or sulfone; Y4 = (un)substituted C2-7 alkyl, C2-7 alkenyl, C2-7 alkynyl or C3-7 cycloalkyl; Y5 = each (un)substituted Ph, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxadiazolyl, triazolyl, thiadiazolyl, pyrazyl, pyridyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, naphthalenyl, quinolonyl, purinyl, indolyl, benzofuranlyl; R1 = H CORa, SO2Ra (where Ra = H, each (un)substituted C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, or C1-5 acyl); R2, R3 = H, each (un)substituted C1-5 alkyl, C1-5 alkenyl, or C1-5 alkynyl, or R2 and R3 may be taken together with the nitrogen of R3 attachment to form piperidine or pyrrolidine or azepine] and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof are prepared These compds. are novel non-peptidic NPY Y2 receptor inhibitors and useful in treating or preventing anxiolytic disorders or depression, injured mammalian nerve tissue, conditions responsive to treatment through administration of a neurotrophic factor, neurol. disorders, bone loss, substance related disorders, obesity, or an obesity-related disorder. They are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of involution and

10565979.trn

L5 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
infertility. Thus, to a soln. of 1-[6-(1-benzylpiperidin-4-ylamino)-2,3-dihydroindol-1-yl]ethanone > (250 mg, 0.72 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added cinnamoyl chloride (160 mg, 0.93 mmol) and triethylamine (TEA, 0.30 mL, 2.2 mmol). The mixt. was stirred at 25° for 16 h to give, after purifn. by preparative TLC (PTLC, 20% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to give 290 mg (85%)  
trans-N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzylpiperidin-4-yl)-3-phenylacrylamide (II). II and trans-N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentylethyl)piperidin-4-yl]acrylamide in vitro inhibited the binding of [125I]PYY to KAN-Ts endogenously expressing Y2 receptor with IC<sub>50</sub> 4.0 and 0.1  $\mu$ M, resp.  
IT 848951-93-9P, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-[1-[(ethylcarbamoyl)(phenyl)methyl]piperidin-4-yl]-3-phenylacrylamide  
848951-94-0P, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-[1-[(ethylcarbamoyl)(phenyl)methyl]piperidin-4-yl]-3-phenylacrylamide trifluoroacetate  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 6-aminoindole and 7-amino-1,2,3,4-tetrahydroquinoline derivs. as non-peptidic neuropeptide Y (NPY) Y2 receptor inhibitors)  
RN 848951-93-9 CAPLUS  
CN 1-Piperidineacetamide,  
4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]-N-ethyl- $\alpha$ -phenyl- (CA INDEX NAME)  
3-phenyl-2-propen-1-yl]amino]-N-ethyl- $\alpha$ -phenyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 848951-94-0 CAPLUS  
CN 1-Piperidineacetamide,  
4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]-N-ethyl- $\alpha$ -phenyl-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 848951-93-9  
CMP C34 H38 N4 O3


Double bond geometry as shown.

L5 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2005:136598 Document No. 142:240323 Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT<sub>6</sub> receptor affinity. Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto;  
Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich (Laboratorios del Esteve S. A., Spain). PCT Int. Appl. WO 2005014045 A1 20050217, 427 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,  
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-EP8514 20040729. PRIORITY: ES 2003-1815 20030730.  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention relates to an active substance combination comprising at least one compound I [R<sub>1</sub>-R<sub>4</sub> = H, halo, alkyl, etc.; R<sub>5</sub> = H, alkyl, (un)saturated cycloalkyl; R<sub>6</sub>-R<sub>9</sub> = H, alkyl, (un)saturated cycloalkyl, etc.;  
A = CHR<sub>10</sub>, CHR<sub>10</sub>CH<sub>2</sub>; B = alkyl, (un)saturated cycloalkyl, etc.; R<sub>10</sub> = H, alkyl, (un)saturated cycloalkyl, etc.; R<sub>11</sub> = alkyl, (un)saturated cycloalkyl, etc.; NR<sub>10</sub>R<sub>11</sub> = (un)saturated heterocyclyl; R<sub>18</sub> = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y<sub>5</sub>-receptor affinity, and at least one compound with 5-HT<sub>6</sub> receptor affinity (such as II [R<sub>1</sub> = H, alkyl, Ph, CH<sub>2</sub>Ph; R<sub>2</sub> = NR<sub>4</sub>R<sub>5</sub>, (un)saturated (hetero)cycloalkyl, etc.; R<sub>3</sub> = H, alkyl; R<sub>4</sub>, R<sub>5</sub> = H, alkyl; or NR<sub>4</sub>R<sub>5</sub> = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.  
Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y<sub>5</sub> and 5-HT<sub>6</sub> binding (data given for representative compds.).  
IT 845525-12-4P 845525-13-5P 845525-14-6P  
845525-15-7P 845525-16-8P 845525-17-9P  
845525-18-0P 845525-19-1P  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT<sub>6</sub> receptor affinity)  
RN 845525-12-4 CAPLUS  
CN Benzoic acid, 2-[[1-[2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl]-4-piperidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


L5 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2




L5 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845525-13-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-phenyl- (CA INDEX NAME)




RN 845525-14-6 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845525-15-7 CAPLUS  
CN 1-Piperidineacetamide,  
N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)


10565979.trn

L5 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● 2 HCl


RN 845525-16-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



RN 845525-17-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 845525-18-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)



RN 845525-19-1 CAPLUS

L5 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2005:136561 Document No. 142:240311 Preparation of N-carbazolyl [(phenylamino)piperidinyl]acetamide derivatives as neuro peptide y5 ligands for the treatment of obesity. Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Fisas Escasany, Maria Angeles; Buschmann, Helmut Heinrich (Laboratorios del Esteve S. A., Spain). PCT Int. Appl. WO 2005013990 A1 20050217, 48 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CV, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-EP8517 20040729. PRIORITY: ES 2003-1813 20030730.

GI



AB Title compds. represented by the formula I [wherein m = 0-4; n = 0-3; p = 0-4; R1-R4 = independently H, halo, OR8, etc.; R5 = H, (cyclo)aliphatic radical; R6-R8 = independently H or prodrug-moiety; and physiol. acceptable salts or solvates thereof] were prepared as neuro peptide Y5 (NPY5) ligands (no data). For example, I (R1 = OH, R2-R4 = H, R5 = Me, m = 1, n = p = 0) was given in a multi-step synthesis starting from the reaction of 3-amino-9-methyl-9H-carbazole with chloroacetyl chloride. Thus, the title compds. are useful as NPY5 ligands in the treatment of obesity for humans or animals.

IT 844642-86-0P, 2-[4-(3-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-methyl-9H-carbazol-3-yl)acetamide 844642-89-3P,

2-[4-(4-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-methyl-9H-carbazol-3-yl)acetamide 844642-90-6P,

2-[4-(5-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-methyl-9H-carbazol-3-yl)acetamide 844642-91-7P,

2-[4-(6-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-methyl-9H-carbazol-3-yl)acetamide 844642-92-8P,

2-[4-(3-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-ethyl-9H-carbazol-3-yl)acetamide 844642-93-9P,


2-[4-(4-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-ethyl-9H-carbazol-3-yl)acetamide 844642-94-0P,

2-[4-(5-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-ethyl-9H-carbazol-3-yl)acetamide 844642-95-1P,

2-[4-(6-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-ethyl-9H-carbazol-3-yl)acetamide

L5 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




L5 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-carbazolyl [(phenylamino)piperidinyl]acetamide derivs. as neuro peptide Y5 ligands for treatment of obesity)


RN 844642-86-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 844642-89-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 844642-90-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[5-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 844642-91-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)




L5 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 844642-92-8 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 844642-93-9 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 844642-94-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[5-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 844642-95-1 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2005:136559 Document No. 142:240321 Preparation of  
(phenylamino)piperidinylacetamides and related compounds as neuropeptide  
Y5 (NPY5) ligands for the treatment of obesity.. Torrens Jover, Antoni;  
Mas Prio, Josep; Fiasas Escosany, Maria Angeles (Laboratorios del Esteve  
S.A., Spain).. PCT Int. Appl. WO 2005013988 A1 20050217, 149 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,  
BY,  
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,  
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG,  
CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR,  
NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION:  
WO 2004-EP8508 20040729. PRIORITY: ES 2003-1813 20030730.  
GI



AB Title compds. [I; R1-R4 = H, halo, NO2, cyano, (substituted) (unsatd.)  
aliphatic, (hetero)cycloaliphatic, aryl, heteroaryl, etc.; R5 = H,  
(substituted) (unsatd.) aliphatic, cycloaliphatic; R6-R9 = H, cyano,  
(substituted) (unsatd.) aliphatic, (hetero)cycloaliphatic, etc.; A =  
CHR18, CHR18CH2; B = (substituted) (unsatd.) aliphatic, cycloaliphatic,  
etc.; R10 = H, (substituted) (unsatd.) aliphatic, (hetero)cycloaliphatic,  
aryl, heteroaryl, etc.; R11 = (substituted) (unsatd.) aliphatic,  
(hetero)cycloaliphatic, aryl, heteroaryl, etc.; R10R11 = (substituted)  
(aromatic) heterocyclyl; R18 = H, (substituted) (unsatd.) aliphatic,  
(hetero)cycloaliphatic, aryl, heteroaryl, etc.], were prepared. Thus,  
1-(4-methyl-2-hydroxymethylphenylamino)piperidine dihydrochloride,  
2-chloro-N-phenylacetamide, and K2CO3 were stirred together overnight in  
DMF to give 63%  
4-[2-(2-hydroxymethyl-4-methylphenylamino)piperidin-1-yl]-  
N-phenylacetamide. Tested I showed NPY5 binding with IC50 = 40.1-80.9  
nM.

I are useful for the regulation of disorders of food ingestion, such as  
obesity, anorexia, cachexia, bulimia or type II diabetes, for the  
prophylaxis and/or treatment of disorders of the peripheral nervous  
system, disorders of the central nervous system, anxiety, depression,  
cognitive disorders, preferably memory disorders, cardiovascular  
diseases,  
pain, epilepsy, arthritis, hypertensive syndrome, inflammatory diseases,  
immune diseases and other NPY5 mediated disorders.

IT 844642-92-8P 844642-93-9P 844642-95-1P  
845525-13-5P 845525-14-6P 845525-16-8P  
845525-17-9P 845525-18-0P 845525-19-1P  
845553-25-5P 845553-26-6P 845553-27-7P  
845553-28-8P 845553-29-9P 845553-30-2P  
845553-31-3P 845553-32-4P 845553-33-5P  
845553-34-6P 845553-35-7P 845553-36-8P

L5 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

845553-37-9P 845553-38-0P 845553-39-1P  
845553-40-4P 845553-41-5P 845553-42-6P  
845553-43-7P 845553-44-8P 845553-45-9P  
845553-46-0P 845553-47-1P 845553-48-2P  
845553-49-3P 845553-50-6P 845553-51-7P  
845553-52-8P 845553-53-9P 845553-54-0P  
845553-55-1P 845553-56-2P 845553-57-3P  
845553-58-4P 845553-59-5P 845553-60-8P  
845553-61-9P 845553-62-0P 845553-63-1P  
845553-64-2P 845553-65-3P 845553-66-4P  
845553-67-5P 845553-68-6P 845553-69-7P  
845553-70-0P 845553-71-1P 845553-72-2P  
845553-73-3P 845553-74-4P 845553-75-5P  
845553-76-6P 845553-77-7P 845553-78-8P  
845553-79-9P 845553-80-2P 845553-81-3P  
845553-82-4P 845553-83-5P 845553-84-6P  
845553-85-7P 845553-86-8P 845553-87-9P  
845553-88-0P 845553-89-1P 845553-90-4P  
845553-91-5P 845553-92-6P 845553-93-7P  
845553-94-8P 845553-95-9P 845553-96-0P  
845553-97-1P 845553-98-2P 845553-99-3P  
845554-00-9P 845554-01-0P 845554-02-1P  
845554-03-2P 845554-04-3P 845554-05-4P  
845554-06-5P 845554-07-6P 845554-08-7P  
845554-09-8P 845554-10-1P 845554-11-2P  
845554-12-3P 845554-13-4P 845554-14-5P  
845554-15-6P 845554-16-7P 845554-17-8P  
845554-18-9P 845554-19-0P 845554-20-3P  
845554-21-4P 845554-22-5P 845554-23-6P  
845554-24-7P 845554-25-8P 845554-26-9P  
845554-27-0P 845554-28-1P 845554-29-2P  
845554-30-5P 845554-31-6P 845554-32-7P  
845554-33-8P 845554-34-9P 845554-35-0P  
845554-36-1P 845554-37-2P 845554-38-3P  
845554-39-4P 845554-40-7P 845554-41-8P  
845554-42-9P 845554-43-0P 845554-44-1P  
845554-45-2P 845554-46-3P 845554-47-4P  
845554-48-5P 845554-49-6P 845554-50-9P  
845554-51-0P 845554-52-1P 845554-53-2P  
845554-54-3P 845554-55-4P 845554-56-5P  
845554-57-6P 845554-58-7P 845554-59-8P  
845554-60-1P 845554-61-2P 845554-62-3P  
845554-63-4P 845554-64-5P 845554-65-6P  
845554-66-7P 845554-67-8P 845554-68-9P  
845554-69-0P 845554-70-3P 845554-71-4P  
845554-72-5P 845554-73-6P 845554-74-7P  
845554-75-8P 845554-76-9P 845554-77-0P  
845554-78-1P 845554-79-2P 845554-80-5P  
845554-81-6P 845554-82-7P 845554-83-8P  
845554-84-9P 845554-85-0P 845554-86-1P  
845554-87-2P 845554-88-3P 845554-89-4P  
845554-90-7P 845554-91-8P 845554-92-9P  
845554-93-0P 845554-94-1P 845554-95-2P  
845554-96-3P 845554-97-4P 845554-98-5P  
845554-99-6P 845555-76-2P 845555-77-3P  
845555-78-4P 845555-93-3P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
(claimed compd.; prepn. of phenylaminopiperidinylacetamides and  
related  
compds. as neuropeptide Y5 ligands for the treatment of obesity)  
RN 844642-92-8 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[3-hydroxy-2-  
(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 844642-93-9 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[4-hydroxy-2-  
(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 844642-95-1 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-hydroxy-6-  
(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845525-13-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-  
phenyl- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845525-14-6 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-  
(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845525-16-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(9-  
oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 845525-17-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-  
oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 845525-18-0 CAPLUS  
CN 1-Piperidineacetamide,  
N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-(hydroxymethyl)-  
4-methylphenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845525-19-1 CAPLUS  
CN 1-Piperidineacetamide,  
N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-(hydroxymethyl)-  
6-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-25-5 CAPLUS  
CN 1-Piperidineacetamide,  
4-[[2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl-  
(CA INDEX NAME)




RN 845553-26-6 CAPLUS  
CN 1-Piperidineacetamide,  
4-[[2-(hydroxymethyl)phenyl]amino]-N-5-quinolinyl-  
(CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-27-7 CAPLUS  
CN 1-Piperidineacetamide,  
4-[[2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl-  
(CA INDEX NAME)




RN 845553-28-8 CAPLUS  
CN 1-Piperidineacetamide,  
4-[[2-(hydroxymethyl)phenyl]amino]-N-8-quinolinyl-  
(CA INDEX NAME)



RN 845553-29-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845553-30-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-5-quinolinyl- (CA INDEX NAME)



PAGE 2-A




RN 845553-33-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)



RN 845553-34-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-5-quinolinyl- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 845553-31-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)



RN 845553-32-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-8-quinolinyl- (CA INDEX NAME)




RN 845553-35-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




RN 845553-36-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-8-quinolinyl- (CA INDEX NAME)

10565979.trn

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-37-9 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-38-0 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-42-6 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 845553-43-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845553-44-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845553-45-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-39-1 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-40-4 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-41-5 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-46-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-5-quinolinyl- (CA INDEX NAME)

PAGE 1-A



Cl


PAGE 2-A

RN 845553-47-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-5-quinolinyl- (CA INDEX NAME)

10565979.trn

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




RN 845553-48-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)


PAGE 2-A




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-49-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




RN 845553-50-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 845553-51-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)



RN 845553-52-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




RN 845553-53-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)



RN 845553-54-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-8-quinolinyl- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 845553-55-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-8-quinolinyl- (CA INDEX NAME)



10565979.trn

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 845553-56-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-8-quinolinyl- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-57-3 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-58-4 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-59-5 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845553-60-8 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-61-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-62-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845553-63-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845553-64-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-65-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845553-66-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845553-67-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 845553-71-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845553-72-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)



RN 845553-73-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845553-74-4 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-2-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-75-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-hydroxy-9H-fluoren-2-yl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-68-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845553-69-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845553-70-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-76-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-hydroxy-9H-fluoren-2-yl)- (CA INDEX NAME)



RN 845553-77-7 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-2-yl)-4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845553-78-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-hydroxy-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845553-79-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-chloro-6-(hydroxymethyl)phenyl]amino]-N-(9-hydroxy-9H-fluoren-2-yl)- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-80-2 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845553-81-3 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-82-4 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-83-5 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 845553-87-9 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-88-0 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845553-89-1 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-90-4 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845553-91-5 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[4,5-difluoro-2-


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845553-84-6 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845553-85-7 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-86-8 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-[3-(1-hydroxyethyl)phenyl]- (CA INDEX NAME)




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 845553-87-9 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-92-6 CAPLUS  
CN 1-Piperidineacetamide, N-1,3-benzodioxol-5-yl-4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845553-93-7 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845553-94-8 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845553-95-9 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-96-0 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




RN 845553-97-1 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(4-fluoro-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




RN 845553-98-2 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(2-(hydroxymethyl)-6-methoxyphenyl)amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-02-1 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(1-(hydroxyethyl)-2-(hydroxymethyl)phenyl)amino]-N-[4-(1-(hydroxyethyl)phenyl)- (CA INDEX NAME)




RN 845554-03-2 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(1-(hydroxyethyl)-2-(hydroxymethyl)phenyl)amino]-N-[4-(1-(hydroxyethyl)phenyl)- (CA INDEX NAME)




RN 845554-04-3 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(1-(hydroxyethyl)-2-(hydroxymethyl)phenyl)amino]-N-[4-(1-(hydroxyethyl)phenyl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845553-99-3 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




RN 845554-00-9 CAPLUS  
CN 1-Piperidineacetamide, N-(4-(1-(hydroxyethyl)phenyl)-4-[(2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




RN 845554-01-0 CAPLUS  
CN 1-Piperidineacetamide, N-(4-(1-(hydroxyethyl)phenyl)-4-[(2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-05-4 CAPLUS  
CN 1-Piperidineacetamide, N-(4-(1-(hydroxyethyl)phenyl)-4-[(2-(hydroxymethyl)phenyl)amino]-N-[4-(1-(hydroxyethyl)phenyl)- (CA INDEX NAME)




RN 845554-06-5 CAPLUS  
CN 1-Piperidineacetamide, N-(4-(1-(hydroxyethyl)phenyl)-4-[(2-(hydroxymethyl)phenyl)amino]-N-[4-(1-(hydroxyethyl)phenyl)- (CA INDEX NAME)




RN 845554-07-6 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-08-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-09-8 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-10-1 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-11-2 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-16-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-17-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 845554-18-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-19-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-12-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-13-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 845554-14-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 845554-15-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-20-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)



RN 845554-21-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-22-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-23-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-24-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-25-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-26-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-30-5 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)



RN 845554-31-6 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-32-7 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-33-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-27-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-28-1 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-29-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(2,3-dihydro-1-oxo-1H-inden-5-yl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-34-9 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)



RN 845554-35-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-bromo-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)




RN 845554-36-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)




RN 845554-37-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-38-3 CAPLUS  
CN 1-Piperidineacetamide, N-3-dibenzofuranyl-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)



RN 845554-39-4 CAPLUS  
CN 1-Piperidineacetamide, N-3-dibenzofuranyl-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-40-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845554-41-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-46-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 845554-47-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-48-5 CAPLUS  
CN 1-Piperidineacetamide, N-(4-cyclohexylphenyl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-49-6 CAPLUS


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-42-9 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-2-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)



RN 845554-43-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-2-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-44-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-45-2 CAPLUS

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845554-50-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)



RN 845554-51-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845554-52-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]-N-3-quinolinyl- (CA INDEX NAME)




RN 845554-53-2 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-54-3 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-55-4 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-56-5 CAPLUS  
CN 1-Piperidineacetamide, N-(4-benzoylphenyl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-60-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)



RN 845554-61-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 845554-62-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




RN 845554-63-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-57-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845554-58-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




RN 845554-59-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-[4-(hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-64-5 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



RN 845554-65-6 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)



RN 845554-66-7 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-67-8 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-68-9 CAPLUS  
CN 1-Piperidineacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-69-0 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845554-70-3 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-71-4 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-76-9 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-77-0 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845554-78-1 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-79-2 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-72-5 CAPLUS  
CN 1-Piperidineacetamide, N-(3-acetylphenyl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-73-6 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845554-74-7 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-75-8 CAPLUS  
CN 1-Piperidineacetamide, N-[3-(1-hydroxyethyl)phenyl]-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-80-5 CAPLUS  
CN 1-Piperidineacetamide, N-(4-acetylphenyl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-81-6 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(1-hydroxyethyl)phenyl]-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)




RN 845554-82-7 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(1-hydroxyethyl)phenyl]-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-83-8 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(1-hydroxyethyl)phenyl]-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-84-9 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(1-hydroxyethyl)phenyl]-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 845554-85-0 CAPLUS  
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-89-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)



RN 845554-90-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-91-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-92-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 845554-86-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-87-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)




RN 845554-88-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845554-93-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (CA INDEX NAME)



RN 845554-94-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-95-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-96-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)

10565979.trn


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
phenoxyphenyl)- (CA INDEX NAME)



RN 845554-97-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 845554-98-5 CAPLUS  
CN 1-Piperidineacetamide,  
N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-  
6-methylphenyl]amino]- (CA INDEX NAME)




RN 845554-99-6 CAPLUS  
CN Benzoic acid, 2-[[1-[2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl]-4-piperidinyl]amino]-, methyl ester (CA INDEX NAME)


L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 845555-76-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




RN 845555-77-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)



RN 845555-78-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
RN 845555-93-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]-N-6-quinolinyl- (CA INDEX NAME)



IT 845525-12-4P 845525-15-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of phenylaminopiperidinylacetamides and related compds.)


as neuropeptide Y5 ligands for the treatment of obesity)

RN 845525-12-4 CAPLUS  
CN Benzoic acid, 2-[[1-[2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl]-4-piperidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 845525-15-7 CAPLUS  
CN 1-Piperidineacetamide,  
N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-  
6-methylphenyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)





● 2 HCl

10565979.trn

L5 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2003:300616 Document No. 138:321298 Preparation of succinoylamino heterocycles as A $\beta$  peptide production inhibitors. Thompson, Lorin A.; Kasireddy, Padmaja (USA). U.S. Pat. Appl. Publ. US 20030073701 A1 20030417, 57 pp. (English). CODEN: USXXCO. APPLICATION: US 2001-823820 20010331.


GI



AB This invention relates to novel succinoylamino heterocycles [I; R11 = H, CH3, LZ, OH, CH2OH, CONH2, COOCH2CH3; R12 = H, LZ; LZ = CH3, CH2C6H5, 2-CH3C6H4, 3-CF3C6H4, 4-FC6H4, CH2CH2OH, CH2CH3, CH2CH:CH2C6H5, 2,6-(CH3)2C6H3, R10; R10 = CH2COOCH2CH3, COCH3, (4-ClC6H4)2CH; X = CH, N, COOCH2CH3, CN(CH3)2, COH, CCH3, COOCH3, CONH2, COOCH2CH3, etc.; e.g.


II] having drug and bio-affecting properties, their pharmaceutical compns. and methods of use. These novel compds. inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A $\beta$ -peptide, thereby acting to prevent the formation of neurul. deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurul. disorders related to  $\beta$ -amyloid production such as Alzheimer's disease and Down's Syndrome. Although the methods of preparation are not claimed, .apprx.130 example prepn. are included. I inhibit the activity of  $\gamma$ -secretase, as determined by the A $\beta$  immunopptn. assay; they inhibit A $\beta$  protein production with an IC50 or KI value of <100  $\mu$ M, but no values are shown for individual I. IT 365539-16-8P 365539-59-9P 365539-60-2P

L5 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 365539-61-3 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[(3-methoxyphenyl)amino]- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365539-63-5 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[(3-methoxy-4-methylphenyl)amino]- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365539-67-9 CAPLUS  
 CN 1-Piperidinebutanamide,  $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-4-[[4-(trifluoromethyl)phenyl]amino]-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 365539-61-3P 365539-63-5P 365539-67-9P  
 365539-69-1P 365539-70-4P 365539-71-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of succinoylamino heterocycles as A $\beta$  peptide prodn. inhibitors)


RN 365539-16-8 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(aminocarbonyl)- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo-4-(phenylamino)- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365539-59-9 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(1,3-benzodioxol-5-ylamino)- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 365539-60-2 CAPLUS  
 CN 1-Piperidinebutanamide,  $\beta$ -(2-methylpropyl)- $\gamma$ -oxo-4-(phenylamino)- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 365539-69-1 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(1,3-benzodioxol-5-ylbenzoylamino)- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365539-70-4 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(benzoylphenylamino)- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 365539-71-5 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[benzoyl(3-methoxyphenyl)amino]- $\beta$ -(2-methylpropyl)- $\gamma$ -oxo- $\alpha$ -propyl-, ( $\alpha$ S, $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



10565979.trn

L5 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2003:97412 Document No. 138:153539 Preparation of  
2-(piperidin-1-yl)acetamides as NMDA receptor antagonists. Domany,  
Gyorgy; Horvath, Csilla; Farkas, Sandor; Barta Szalai, Gisella; Nagy,  
Jozsef; Kolok, Sandor; Kovacs Bozo, Eva; Borza, Istvan; Vago, Istvan;  
Bielik, Attila; Szendrei, Mrs. Gyorgyi Ignaczne; Keseru, Gyorgy (Richter  
Gedeon Vegyeszeti Gyar Rt., Hung.). PCT Int. Appl. WO 2003010159 A1  
20030206, 132 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ,  
OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI,  
CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL,  
PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO  
2002-HU71 20020723. PRIORITY: HU 2001-200103055 20010724; HU  
2002-200202213 20020710.

GI




AB The title compds. I [wherein V and U = independently H, halo, OH, CN,  
NO2,  
NH2, alkylsulfonyloxy, carboxyl, CF3, CF3O, alkyl-SO2-NHCH2,  
NH2-(CH2)1-4-SO2NH, NH2-(CH2)1-4-CONH, sulfamoyl, CHO, aminomethyl,  
HOCH2,  
alkyl, alkoxyethyl, halo-CH2, tetrazolyl, alkoxy(carbonyl), alkanoyloxy,  
Ph, (un)substituted alkylamino, arylamino, aralkylamino,  
alkylsulfonamido,  
alkanolamido, arylsulfonamido, or alkoxy groups; or the neighboring V  
and  
U together form (un)substituted 4-7 membered ring with the atoms  
attached;  
W and X = independently CO, CH2, or CH-alkyl; Y = O, (cyclo)alkylene,  
alkynylene, aminocarbonyl, NH, N-alkyl, CH2O, CH(OH), or OCH2; Z = H,  
halo, NO2, NH2, alkyl, alkoxy, CN, CF3, OH, or CO2H; R1 and R2 =  
independently H or alkyl; or R1 and R2 together form (un)substituted  
C1-C3

L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
bridge; n and m = independently 0-3 with restriction that n and m ≠  
0 at the same time; with provisos] and optical antipodes, racemates, or  
pharmaceutically acceptable salts thereof are prep. as NMDA receptor  
antagonists, and moreover most of the compds. are selective antagonist of  
NR2B subtype of NMDA receptor. For example,  
2-[4-(4-fluorobenzyl)piperidin-1-yl]-2-oxoacetic acid (prepn given) was  
treated with 5-amino-1,3-dihydroindol-2-one in DMF in the presence of  
Et3N  
and HBTU to afford the acetamide II (48%). II showed IC50 of 0.0007 μM  
against NMDA in rat. Formulations contg. I as an active ingredient were  
also described.


IT 496057-18-2P 496058-31-2P 496058-32-3P  
496058-35-6P 496058-37-8P 496058-38-9P  
496058-60-7P 496058-61-8P 496058-62-9P  
496058-63-0P 496058-64-1P 496058-65-2P  
496058-66-3P 496058-67-4P 496058-69-6P  
496058-70-9P 496058-79-8P 496058-80-1P  
496058-81-2P 496058-82-3P 496058-83-4P  
496058-84-5P 496058-85-6P 496058-86-7P  
496058-87-8P 496058-90-3P 496058-96-9P  
496058-97-0P 496058-98-1P 496058-99-2P  
496059-00-8P 496059-01-9P 496059-14-4P  
496059-15-5P 496059-16-6P 496059-20-2P  
496059-21-3P 496059-22-4P 496059-23-5P  
496059-24-6P 496059-90-6P 496059-91-7P  
496059-92-8P 496059-93-9P 496059-94-0P  
496059-96-2P 496059-97-3P 496059-98-4P  
496059-99-5P 496060-00-5P 496060-01-6P  
496060-16-3P 496060-17-4P 496060-18-5P  
496060-19-6P 496060-20-9P 496060-21-0P  
496060-22-1P 496060-23-2P 496060-24-3P  
496060-25-4P 496060-26-5P 496060-27-6P  
496060-28-7P 496060-29-8P 496060-30-1P  
496060-31-2P 496060-32-3P 496060-33-4P  
496060-34-5P 496060-35-6P 496060-36-7P  
496060-37-8P 496060-38-9P 496060-39-0P  
496060-40-3P 496060-41-4P 496060-42-5P  
496060-43-6P 496060-44-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(NMDA receptor antagonist; preparation of piperidinylacetamides by  
coupling  
reactions as NMDA receptor antagonists)

RN 496057-18-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[methyl(4-methylphenyl)amino]-N-[4-  
[(methylsulfonyl)amino]phenyl]- (CA INDEX NAME)




RN 496058-31-2 CAPLUS


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-[4-  
[(methylsulfonyl)amino]phenyl]-α-oxo- (CA INDEX NAME)




RN 496058-32-3 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[(4-  
chlorophenyl)methylamino]-α-oxo- (CA INDEX NAME)



RN 496058-35-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[methyl(4-methylphenyl)amino]-N-[4-  
[(methylsulfonyl)amino]phenyl]-α-oxo- (CA INDEX NAME)




RN 496058-37-8 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[(4-  
bromophenyl)methylamino]-α-oxo- (CA INDEX NAME)




RN 496058-38-9 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[methyl(4-  
methylphenyl)amino]-α-oxo- (CA INDEX NAME)

10565979.trn


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-60-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-5-benzoxazolyl)- $\alpha$ -oxo- (CA INDEX NAME)



RN 496058-61-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-62-9 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[(4-chlorophenyl)methylamino]- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-63-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)- $\alpha$ -oxo- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-69-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-thioxo-1H-benzimidazol-5-yl)- $\alpha$ -oxo- (CA INDEX NAME)



RN 496058-70-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzothiazolyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-79-8 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-5-benzoxazolyl)-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-80-1 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-64-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-1H-indazol-5-yl- $\alpha$ -oxo- (CA INDEX NAME)



RN 496058-65-2 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzotriazol-6-yl-4-[(4-chlorophenyl)methylamino]- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-66-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]- $\alpha$ -oxo-N-(1,2,3,4-tetrahydro-2-oxo-6-quinoliny)- (CA INDEX NAME)




RN 496058-67-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]- $\alpha$ -oxo-N-


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-81-2 CAPLUS  
CN 1-Piperidineacetamide, N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)



RN 496058-82-3 CAPLUS  
CN 1-Piperidineacetamide, N-1H-indazol-5-yl-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-83-4 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzotriazol-6-yl-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)




RN 496058-84-5 CAPLUS  
CN 1-Piperidineacetamide, N-(2-methyl-1H-benzimidazol-6-yl)-4-[methyl(4-methylphenyl)amino]- $\alpha$ -oxo- (CA INDEX NAME)

10565979.trn


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-85-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[methyl(4-methylphenyl)amino]-α-oxo-N-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- (CA INDEX NAME)



RN 496058-86-7 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-thioxo-1H-benzimidazol-5-yl)-4-[methyl(4-methylphenyl)amino]-α-oxo- (CA INDEX NAME)




RN 496058-87-8 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-6-benzothiazolyl)-4-[methyl(4-methylphenyl)amino]-α-oxo- (CA INDEX NAME)




RN 496058-90-3 CAPLUS


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496058-99-2 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-α-oxo- (CA INDEX NAME)



RN 496059-00-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-1H-indol-5-yl-α-oxo- (CA INDEX NAME)




RN 496059-01-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-α-oxo-N-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- (CA INDEX NAME)




RN 496059-14-4 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(4-hydroxyphenyl)- (CA INDEX NAME)

L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-1H-indol-5-yl-α-oxo- (CA INDEX NAME)



RN 496058-96-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-5-benzoxazolyl)-α-oxo- (CA INDEX NAME)




RN 496058-97-0 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-α-oxo- (CA INDEX NAME)




RN 496058-98-1 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[(4-bromophenyl)methylamino]-α-oxo- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496059-15-5 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[(4-chlorophenyl)methylamino]- (CA INDEX NAME)




RN 496059-16-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-[4-(methylsulfonyl)amino]phenyl]- (CA INDEX NAME)



RN 496059-20-2 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496059-21-3 CAPLUS  
CN 1-Piperidineacetamide, N-[4-(acetylamino)phenyl]-4-[(4-bromophenyl)methylamino]- (CA INDEX NAME)




10565979.trn


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 496059-22-4 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(4-hydroxyphenyl)-  
 4-[(4-bromophenyl)methylamino]-N-(4-hydroxyphenyl)-  
 (CA INDEX NAME)




RN 496059-23-5 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-[4-(methylsulfonyl)amino]phenyl]-  
 (CA INDEX NAME)



RN 496059-24-6 CAPLUS  
 CN 1-Piperidineacetamide,  
 N-(4-hydroxyphenyl)-4-[methyl(4-methylphenyl)amino]-  
 (CA INDEX NAME)




RN 496059-90-6 CAPLUS  
 CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[(4-chlorophenyl)methylamino]-  
 (CA INDEX NAME)




RN 496059-91-7 CAPLUS


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496059-96-2 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzoxazolyl)-  
 (CA INDEX NAME)



RN 496059-97-3 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-chlorophenyl)methylamino]-N-1H-indazol-5-yl-  
 (CA INDEX NAME)




RN 496059-98-4 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-chlorophenyl)methylamino]-N-1H-indazol-6-yl-  
 (CA INDEX NAME)




RN 496059-99-5 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-1H-indol-5-yl-  
 (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-  
 (CA INDEX NAME)



RN 496059-92-8 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-thioxo-6-benzothiazolyl)-  
 (CA INDEX NAME)




RN 496059-93-9 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2-methyl-1H-benzimidazol-6-yl)-  
 (CA INDEX NAME)




RN 496059-94-0 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(1,2,3,4-tetrahydro-2-oxo-6-quinoliny)-  
 (CA INDEX NAME)




L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496060-00-5 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2-methyl-1H-indol-5-yl)-  
 (CA INDEX NAME)



RN 496060-01-6 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzothiazolyl)-  
 (CA INDEX NAME)



RN 496060-16-3 CAPLUS  
 CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-6-benzoxazolyl)-4-[methyl(4-methylphenyl)amino]-  
 (CA INDEX NAME)




RN 496060-17-4 CAPLUS  
 CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-5-benzoxazolyl)-4-[methyl(4-methylphenyl)amino]-  
 (CA INDEX NAME)




10565979.trn


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496060-18-5 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)



RN 496060-19-6 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-1H-indol-5-yl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-20-9 CAPLUS  
CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-21-0 CAPLUS  
CN 1-Piperidineacetamide, N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)

L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 496060-25-4 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-thioxo-1H-benzimidazol-5-yl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-26-5 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-oxo-6-benzothiazolyl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)



RN 496060-27-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2-methyl-1H-indol-5-yl)- (CA INDEX NAME)




RN 496060-28-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2-methyl-1H-benzimidazol-6-yl)- (CA INDEX NAME)




RN 496060-29-8 CAPLUS


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496060-22-1 CAPLUS  
CN 1-Piperidineacetamide, N-1H-indol-5-yl-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)



RN 496060-23-2 CAPLUS  
CN 1-Piperidineacetamide, N-(2,3-dihydro-2-thioxo-6-benzothiazolyl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-24-3 CAPLUS  
CN 1-Piperidineacetamide, 4-[methyl(4-methylphenyl)amino]-N-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- (CA INDEX NAME)




L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 496060-30-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- (CA INDEX NAME)




RN 496060-30-1 CAPLUS  
CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzothiazolyl)- (CA INDEX NAME)



RN 496060-31-2 CAPLUS  
CN 1-Piperidineacetamide, N-(2-methyl-1H-indol-5-yl)-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-32-3 CAPLUS  
CN 1-Piperidineacetamide, N-1H-indazol-5-yl-4-[methyl(4-methylphenyl)amino]- (CA INDEX NAME)




RN 496060-33-4 CAPLUS

10565979.trn


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN 1-Piperidineacetamide,  
 N-1H-indazol-6-yl-4-[methyl(4-methylphenyl)amino]-  
 (CA INDEX NAME)



RN 496060-34-5 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-  
 6-benzoxazolyl)- (CA INDEX NAME)




RN 496060-35-6 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-  
 1H-indol-5-yl)- (CA INDEX NAME)




RN 496060-36-7 CAPLUS  
 CN 1-Piperidineacetamide, N-1H-benzimidazol-6-yl-4-[(4-  
 bromophenyl)methylamino]- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-1H-indol-5-yl-  
 (CA INDEX NAME)




RN 496060-41-4 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-  
 thioxo-6-benzothiazolyl)- (CA INDEX NAME)



RN 496060-42-5 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-  
 thioxo-1H-benzimidazol-5-yl)- (CA INDEX NAME)




RN 496060-43-6 CAPLUS  
 CN 1-Piperidineacetamide, N-(2-methyl-1H-benzimidazol-6-yl)-4-[methyl(4-  
 methylphenyl)amino]- (CA INDEX NAME)




RN 496060-44-7 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-bromophenyl)methylamino]-N-(2,3-dihydro-2-oxo-  
 5-benzoxazolyl)- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 496060-37-8 CAPLUS  
 CN 1-Piperidineacetamide,  
 4-[(4-bromophenyl)methylamino]-N-(3,4-dihydro-3-oxo-  
 2H-1,4-benzoxazin-7-yl)- (CA INDEX NAME)



RN 496060-38-9 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-1H-indazol-6-yl-  
 (CA INDEX NAME)




RN 496060-39-0 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(4-bromophenyl)methylamino]-N-1H-indazol-5-yl-  
 (CA INDEX NAME)



RN 496060-40-3 CAPLUS



L5 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



10565979.trn

L5 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2002;615600 Document No. 137;154934 Preparation of benzimidazoles as  
 trypsin  
 inhibitors. Thies, Claudia; Braun, Christine; Pouzet, Pascale Arielle  
 Jane-Josee; Anderskewitz, Ralf; Disse, Bernd; Dollinger, Horst;  
 Jennewein,  
 Hans Michael; Nar, Herbert; Hasselbach, Kai Malte (Boehringer Ingelheim  
 Pharma K.-G., Germany). PCT Int. Appl. WO 2002062785 A1 20020815, 79 pp.  
 DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,  
 BE,  
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,  
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ,  
 CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,  
 ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2.  
 APPLICATION: WO 2002-EP1221 20020206. PRIORITY: DE 2001-10105628  
 20010208.

GI




AB Title compds. [I; R1 = (substituted) alkyl, alkenyl, alkynyl,  
 phenylalkyl,  
 alkylene-bonded 5-6 membered (saturated) heterocyclyl; R2 = C(:NH)NH2,  
 CH2NH2;  
 R3 = H, (CO2H-, alkylcarbonyl-, heterocyclyl-substituted) alkyl; X = CO,  
 CH2, CH2CH2; R4 = Q1; W = N, CH; A = NR6 if n = 0, or A = O, CHR6, NR6 if  
 n = 1; R5, R6 = H, B(CO)m; B = alkyl, cycloalkyl, Ph, naphthyl, etc.; m =  
 0, 1; or NR5R6 = (substituted) heterocyclyl; n = 0, 1], were prepared  
 Thus,  
 4-(2-chloro-4-fluorophenylamino)-1-piperidine was alkylated with  
 N-[2-(2-[4-(tert-butyloxycarbonylamino)benzyl]ethyl)-1-methyl-benzimidazol-  
 5-yl]-N-methyl-2-chloroacetamide (preparation given) and K2CO3 in DMF  
 for 3 h  
 at 80°-90° followed by elimination of the protective group  
 with CF3CO2H to give 84%  
 N-[2-(4-[aminobenzyl]ethyl)-1-methylbenzimidazol-  
 5-yl]-N-methyl-2-[4-(2-chloro-4-fluorophenylamino)-piperidin-1-  
 yl]acetamide difluoroacetate. The latter inhibited trypsin with IC50 =

L5 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 PAGE 1-B

—NH2

RN 445378-23-4 CAPLUS  
 CN 1-Piperidineacetamide, N-[2-[2-[4-(aminomethyl)phenyl]ethyl]-1-methyl-1H-  
 benzimidazol-5-yl]-4-[(2-chloro-4-fluorophenyl)amino]-N-methyl-,  
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)  
 CM 1  
 CRN 445378-22-3  
 CMP C31 H36 Cl F N6 O



PAGE 1-B

—CH2—NH2


CM 2  
 CRN 76-05-1  
 CMP C2 H F3 O2



IT 445378-10-9P 445378-19-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of benzimidazoles as trypsin inhibitors)

L5 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 0.004-0.03 μM.  
 IT 445378-08-5P 445378-17-6P 445378-23-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of benzimidazoles as trypsin inhibitors)  
 RN 445378-08-5 CAPLUS  
 CN 1-Piperidineacetamide,  
 N-[2-[2-[4-(aminoiminomethyl)phenyl]ethyl]-1-methyl-  
 1H-benzimidazol-5-yl]-N-(1-naphthalenylmethyl)-4-(phenylamino)-,  
 hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 445378-17-6 CAPLUS  
 CN 1-Piperidineacetamide,  
 N-[2-[2-[4-(aminoiminomethyl)phenyl]ethyl]-1-methyl-  
 1H-benzimidazol-5-yl]-N-[(2-chlorophenyl)amino]-N-methyl-, hydrochloride  
 (1:2) (CA INDEX NAME)

PAGE 1-A




●2 HCl

L5 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 445378-10-9 CAPLUS  
 CN 1-Piperidineacetamide, N-[2-[2-(4-cyanophenyl)ethyl]-1-methyl-1H-  
 benzimidazol-5-yl]-N-(1-naphthalenylmethyl)-4-(phenylamino)- (CA INDEX  
 NAME)





RN 445378-19-8 CAPLUS  
 CN 1-Piperidineacetamide, 4-[(2-chlorophenyl)amino]-N-[2-[2-(4-  
 cyanophenyl)ethyl]-1-methyl-1H-benzimidazol-5-yl]-N-methyl- (CA INDEX  
 NAME)



10565979.trn

L5 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2002:408646 Document No. 137:5994 Preparation of biphenylcarboxamides as  
lipid lowering agents. Meerpoel, Lieven; Backx, Leo Jacobus Jozef  
(Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2002042271 A2  
20020530, 49 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE,  
BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT,  
LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN:  
PIXXD2. APPLICATION: WO 2001-EP13316 20011115. PRIORITY: EP 2000-204150  
20001121.

GI



AB The title comps. [I; p1-p3 = 1-3; R1 = H, alkyl, alkoxy, etc.; R2 = H, alkyl, alkoxy, halo; CF3; R3 = H, alkyl; R4 = alkyl, alkoxy, halo, CF3; Z = pyrrolidino, piperidino (N-atom attached to Ph ring, etc.); A = a bond, (un)substituted alkanediyl; B = H, alkyl, (un)substituted aryl, etc.], useful for the treatment of hyperlipidemia, obesity and type II diabetes, were prepared. Thus, reacting N-(4-[(1E)-3-amino-1-propenyl]phenyl)-4'-trifluoromethyl-[1,1'-biphenyl]-2-carboxamide (prepn.given) with Me 2-bromo-2-phenylacetate in the presence of Et3N and Bu4NI in THF afforded II. The comps. I were tested for inhibition of ApoB secretion and biol. data were given.

IT 432023-32-0P 432023-36-4P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU

L5 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2002:72044 Document No. 136:134675 Preparation of heterocyclic amino alcohol

beta-3 adrenergic receptor agonists. Ashwell, Mark Anthony; Solvibile, William Ronald; Quagliato, Dominick Anthony; Molinari, Albert John (American Home Products Corporation, USA). PCT Int. Appl. WO 2002006229 A2 20020124, 208 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US22327 20010716. PRIORITY: US 2000-218628P 20000717.

AB This invention provides A-U-(OH)CH2NCH2CH2VC6H4WZ-p (1; Z = (1-Y-X-substituted piperidin-4-yl)) or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes. beta-3-Adrenergic receptor EC50 and maximal response (IA; % activity compound/% activity isoproterenol) values

are reported for .apprx.100 example comps., e.g. 0.032  $\mu$ M and 1.04 for 4-[4-[2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]phenylamino]piperidine-1-carboxylic acid 2,6-difluorobenzylamide. In 1, A is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, and S, substituted with (R1)m; (b) a Ph ring substituted with (R1)m; (c) a naphthyl ring substituted

with (R1)m; or (d) a Ph fused heterocycle selected from (R1)m-substituted 1,3-dihydro-2-oxo-2H-benzimidazol-4-yl, 1,3-benzodioxol-5-yl, 1,2,3,4-tetrahydro-2-oxoquinolin-5-yl, 1,2,3,4-tetrahydro-1-naphthylideneamino. U is -OCH2- or a bond; V is O

or a bond; W is O, S(O)a, NR2, NC(O)R2; X = SO2, C(O), -(CH2)b, a bond, Ar;

Y is -NR3R4, Het, Ar, alkyl of 1-8 C atoms, O(CH2)dR5. R1 is alkyl of 1-8

C atoms, -OR6, halogen, cyano, cycloalkyl of 3-8 C atoms, trifluoromethyl, CO2R6, -NR6R7, -C(O)NR6R7, -NHC(O)R6, -NR6C(O)NR8R9, -NHSO2R8, -S(O)aR6, -NO2, -O(CH2)eCO2R7, -OC(O)NR6R7, -O(CH2)fOR6, or a 5-6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from O, S, and

N. R2 is H, alkyl of 1-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R3 and R4 are each, independently, H, alkyl of 1-8 C atoms, cycloalkyl of 3-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl group, -(CH2)gR9, -(CH2)hCO2R9, -(CH2)jCR10R11(CH2)kR9, or -(CH2)kCONR12R13; or R3 and R4 may be taken together together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which


may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14. R5 is H; alkyl of 1-8 C atoms optionally substituted by 1-3 substituents selected from hydroxy, halogen and aryl; cycloalkyl of 1-8 C atoms; Ar or Het; R6, R7, and R8 are each, independently, H, or alkyl of 1-8 C atoms, or aryl of 6-10 C atoms, cycloalkyl of 3-8 C atoms, or arylalkyl having 1-8 C atoms

L5 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
(Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of biphenylcarboxamides as lipid lowering agents)


RN 432023-32-0 CAPLUS

CN 1-Piperidineacetamide, N-ethyl- $\alpha$ -phenyl-4-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]amino]- (CA INDEX NAME)



RN 432023-36-4 CAPLUS

CN 1-Piperidineacetamide,  $\alpha$ -phenyl-N-propyl-4-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]amino]- (CA INDEX NAME)



L5 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
in the alkyl moiety; R9 is H; alkyl optionally substituted with 1-3 substituents selected from hydroxy, halogen, and aryl; cycloalkyl of 3-8

C atoms; Ar, or Het; R10 and R11 are each, independently, H, alkyl, or aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R10 and R11 are taken together to form a spiro fused cycloalkyl ring of 3-8 C atoms. R12 and R13 are each, independently, H, alkyl of 1-8 C atoms,

aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and R13 are taken together with the N to which they are attached to form a

3-7 membered satd. heterocycle, which may optionally contain 1-2 addnl.

heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14; R14 is CO2R15 or aryl optionally substituted with a 1-3 substituents selected from -OR15 and cycloalkyloxy of 3-8 C atoms;

R15 is alkyl of 1-8 C atoms or arylalkyl having 1-8 C atoms in the alkyl moiety. Ar is an arom. ring system contg. 1-2 carbocyclic arom. rings having 6-10 C atoms optionally mono, di, or trisubstituted with R16; Het is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, S, and N which may be optionally mono- or disubstituted with R16; or (b) a heterocyclic ring system optionally mono- or disubstituted by

R16 contg. a 5-6 membered heterocyclic ring fused to one or two carbocyclic

or heterocyclic rings such that the heterocyclic ring system contains 1-4 heteroatoms selected from O, S, and N; R16 is aryl, halogen, alkyl of 1-8 C atoms, -OR17, cycloalkyl of 3-8 C atoms, trifluoromethyl, cyano, -CO2R17, -CONR17R18, -SO2NR17R18, -NR17OR18, -NR19CONR17R18, -NR17R18, -NR17OR18, -NO2, -O(CH2)pCO2R17, -OCONR17R18, -S(O)nR17, -O(CH2)qOR17,

or a 5-6 membered heterocyclic ring contg. 1-4 heteroatoms selected from O,

S and N. R17, R18, and R19 are each, independently, H, alkyl of 1-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl moiety, or aryl optionally mono, di, or trisubstituted with halogen, cyano, nitro, hydroxy, alkyl of 1-8 C atoms, or alkoxy of 1-8 C atoms; or when R17 and R18 are contained on a common N, R17 and R18 may be taken together with the N to which they are attached to form a 3-7 membered satd. heterocycle,

which may optionally contain 1-2 addnl. heteroatoms selected from O and S.


A = 0-2; b = 1-6; d = 0-3; e = 1-6; f = 1-6; g = 0-6; h = 0-6; j = 0-6; k = 0-6; m = 0-2; p = 1-6; q = 1-6. Methods of prepn. are claimed, comprising (a) reacting AOCHE2-substituted oxirane or a protected form thereof in which a reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 (U = -OCH2-). (b) reacting A-substituted oxirane or a protected form thereof in which a reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U represents a bond;. (c) reacting ACH (OPr)CH2I, wherein Pr is a protecting group, with H2NCH2CH2VC6H4WZ-p

or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein



U = -OCH2-. (d) reacting ACH (OH)CH2NH2 or a protected form thereof in

10565979.trn

L5 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 which any reactive substituent group is protected, with HO2CCH2VC6H4WZ-p  
 or a protected form thereof in which a reactive substituent group is  
 protected; and if required removing any protecting group to give 1  
 wherein  
 U = -OCH2-. (e) removing any protecting group from 1 in which at least  
 one substituent carries a protecting group to give 1; or (f) converting a  
 basic compd. 1 to a salt thereof by reaction with a pharmaceutically  
 acceptable acid; or (g) converting 1 having one or more reactive  
 substituent groups to a different 1; or (h) isolating an isomer of 1 from  
 a mixt. thereof. More than 100 example preps. are included.  
 IT 392638-32-3, [2-[4-[1-(4-Morpholin-4-yl-4-oxobutyl)piperidin-4-  
 ylamino]phenyl]ethyl]carbamic acid tert-butyl ester  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant; preparation of heterocyclic amino alc. beta-3 adrenergic  
 receptor agonists)  
 RN 392638-32-3 CAPLUS  
 CN Carbamic acid, [2-[4-[[1-[4-(4-morpholinyl)-1,4-dioxobutyl]-4-  
 piperidinyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)




L5 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 2001:747771 Document No. 135:303912 Preparation of  
 succinoylamino-heterocycles as Aβ peptide production inhibitors.  
 Thompson, Lorin Andrew; Kasireddy, Padmaja (Dupont Pharmaceuticals  
 Company, USA). PCT Int. Appl. WO 2001074796 A1 20011011, 145 pp.  
 DESIGNATED STATES: W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI,  
 GB,  
 HU, IL, IN, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI,  
 SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR. (English).  
 CODEN: PIXXD2. APPLICATION: WO 2001-US10297 20010330. PRIORITY: US  
 2000-FV193490 20000331.  
 GI




AB Title compds. [I; R11 = H, CH3, LZ, OH, CH2OH, CONH2, COOCH2CH3; R12 = H,  
 LZ; LZ = CH3, CH2C6H5, 2-CH3C6H4, 3-CF3C6H4, 4-FC6H4, CH2CH2OH, CH2CH3,  
 CH2CH=CH2C6H5, 2,6-(CH3)2C6H3, R10; R10 = CH2COOCH2CH3, COCH3,  
 (4-ClC6H4)2CH; X = CH, N, COOCH2CH3, CN(CH3)2, COH, CCH3, COOCH3,  
 CCONH2,  
 COOCH2CH3, etc.] are prepared and are useful as remedies of neuron.  
 disorders related to β-amyloid production such as Alzheimer's disease  
 and  
 Down's syndrome. Title compds. I inhibit the processing of amyloid  
 precursor protein and, more specifically, inhibit the production of  
 Aβ-peptide, thereby acting to prevent formation of neuron. deposits  
 of amyloid protein. Thus, the title compound II was prepared and in  
 vitro

L5 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 tested for Aβ peptide accumulation inhibition.  
 IT 365539-16-8P 365539-59-9P 365539-60-2P  
 365539-61-3P 365539-63-5P 365539-67-9P  
 365539-69-1P 365539-70-4P 365539-71-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of succinoylaminoheterocycles as Aβ peptide production  
 inhibitors)  
 RN 365539-16-8 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(aminocarbonyl)-β-(2-methylpropyl)-γ-  
 oxo-4-(phenylamino)-α-propyl-, (αS,βR)- (CA INDEX NAME)  
 Absolute stereochemistry.



RN 365539-59-9 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(1,3-benzodioxol-5-ylamino)-β-(2-  
 methylpropyl)-γ-oxo-α-propyl-, (αS,βR)- (CA INDEX  
 NAME)


Absolute stereochemistry.



RN 365539-60-2 CAPLUS  
 CN 1-Piperidinebutanamide, β-(2-methylpropyl)-γ-oxo-4-  
 (phenylamino)-α-propyl-, (αS,βR)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 365539-61-3 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[(3-methoxyphenyl)amino]-β-(2-methylpropyl)-  
 γ-oxo-α-propyl-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 365539-63-5 CAPLUS  
 CN 1-Piperidinebutanamide, 4-[(3-methoxy-4-methylphenyl)amino]-β-(2-  
 methylpropyl)-γ-oxo-α-propyl-, (αS,βR)- (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 365539-67-9 CAPLUS  
 CN 1-Piperidinebutanamide, β-(2-methylpropyl)-γ-oxo-4-  
 4-[[4-(trifluoromethyl)phenyl]amino]-, (αS,βR)- (CA INDEX  
 NAME)

Absolute stereochemistry.


10565979.trn

L5 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 365539-69-1 CAPLUS  
CN 1-Piperidinebutanamide, 4-(1,3-benzodioxol-5-ylbenzoylamino)-β-(2-methylpropyl)-γ-oxo-α-propyl-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 365539-70-4 CAPLUS  
CN 1-Piperidinebutanamide, 4-(benzoylphenylamino)-β-(2-methylpropyl)-γ-oxo-α-propyl-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 365539-71-5 CAPLUS  
CN 1-Piperidinebutanamide, 4-[benzoyl(3-methoxyphenyl)amino]-β-(2-methylpropyl)-γ-oxo-α-propyl-, (αS,βR)- (CA INDEX NAME)


L5 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2000:238056 Document No. 132:274335 Amide derivatives, preparation, pharmaceutical compositions, and methods for using them as selective neuropeptide Y receptor antagonists. Connell, Richard D.; Lease, Timothy G.; Ladouceur, Gaetan H.; Osterhout, Martin H. (Bayer Corporation, USA). U.S. US 6048900 A 20000411, 25 pp. (English). CODEN: USXXAM.  
APPLICATION: US 1998-23498 19980213.  
AB Amide derivs. and methods of administering the compns. to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.  
IT 212052-34-1P 212052-63-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amide derivs. for neuropeptide Y receptor antagonists, preparation, and pharmaceutical compns.)  
RN 212052-34-1 CAPLUS  
CN 1-Piperidineacetamide, 4-(aminocarbonyl)-N-(4-cyclohexylphenyl)-4-(phenylamino)- (CA INDEX NAME)



RN 212052-63-6 CAPLUS  
CN 1-Piperidineacetamide, 4-(aminocarbonyl)-N-(4-benzoylphenyl)-4-(phenylamino)- (CA INDEX NAME)




L5 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.



L5 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
2000:26355 Document No. 132:207824 Synthesis and in Vivo Functional Studies of Ortho-Substituted Phenylpiperazine and N-Substituted 4-N-(o-Methoxyphenyl)aminopiperidine Analogs of WAY100635. Menzies-Harrema, Marguerite M.; Liao, Yi; Boettcher, Henning; Bartoszyk, Gerd D.; Greiner, Hartmut E.; Harting, Juergen; de Boer, Peter; Wikstroem, Rkan V. (Department of Medicinal Chemistry, University of Groningen, Groningen, NL-9713 AV, Neth.). Journal of Medicinal Chemistry, 43(3), 432-439 (English) 2000. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.


GI




AB WAY100635 (I, R = Me) is a silent serotonin 5-HT1A antagonist, which is now widely used to study the 5-HT1A receptor both in vivo and in vitro. In this paper, we describe the synthesis and in vitro (5-HT1A affinity and pA2 values at guinea pig ileum strips) and in vivo (hypothermia and ultrasonic vocalization) pharmacol. at the serotonin 5-HT1A receptor of several closely related analogs of I (R = Me). Test compds. in which the arylpiperazine moiety of I (R = Me) was replaced by an arylaminopiperidine moiety showed no affinity or antagonistic activity at the 5-HT1A receptor.  
Substitution of the o-methoxy group of I (R = Me) by larger fluoroalkoxy or sulfonyloxy substituents did not alter the in vitro or in vivo pharmacol. to any great extent; in vivo both the fluoropropyl analog and the triflate analog were equipotent to WAY100635 itself. The O-desmethyl analog (I, R = H) proved to be the most potent antagonist at the serotonin 5-HT1A postsynaptic receptor sites in this series.  
IT 260360-17-6P 260360-18-7P 260360-27-8P  
260360-28-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (WAY100635 analogs as serotonin 5-HT1A receptor antagonists)  
RN 260360-17-6 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)amino]-N-2-pyridinyl- (CA INDEX NAME)

10565979.trn


L5 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 260360-18-7 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)methylamino]-N-2-pyridinyl-  
(CA INDEX NAME)





RN 260360-27-8 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)amino]-N-2-pyridinyl-,  
hydrochloride (1:?) (CA INDEX NAME)



●<sub>x</sub> HCl

RN 260360-28-9 CAPLUS  
CN 1-Piperidineacetamide, 4-[(2-methoxyphenyl)methylamino]-N-2-pyridinyl-,  
hydrochloride (1:?) (CA INDEX NAME)

L5 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
1999:633519 Document No. 131:257556 Preparation of tetrahydroisoquinoline  
derivatives as cardiovascular agents. Watanabe, Toshihiko; Kakefusa,  
Akio; Kubota, Hideki; Masuda, Noriyuki (Yamanouchi Pharmaceutical Co.,  
Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 11269172 A 19991005 Heisei, 16  
pp. (Japanese). CODEN: JRXRAF. APPLICATION: JP 1998-75646 19980324.




AB The title comp.s. I [R1, R2 = H, alkyl, etc.; X = O, S, etc.; A1 =  
alkylene; A2 = alkylene, or A2 may be nonexistent; A3 = alkylene or A3  
may be nonexistent; ring B = (un)substituted hydrocarbon ring, etc.], useful  
as cardiovascular agents with If current inhibiting effect (no data), are  
prepared For example, the title compound II was prepared

prepared for example; the title compound 11 was prepared  
IT 245057-06-IP 245057-07-2P  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of tetrahydrosequinoline derivs. as cardiovascular  
agents)

```

RN      245057-06-1    CAPLUS
CN      1-Propanone,
1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-[4-[(3,4-
dimethoxyphenyl)amino]-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX
NAME)


```



● 2 HCl


RN 245057-07-2 CAPLUS

L5 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





● x HCl

L5 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN 1-Propanone, 3-[4-(1,3-benzodioxol-5-ylamino)-1-piperidinyl]-1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-, hydrochloride (1:2) (CA INDEX NAME)


 $\bullet_2 \text{HCl}$

L5 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS ON STN  
1999:576930 Document No. 131:199712 Preparation of heterocyclic compounds  
as  
glycine transport inhibitors. Luyten, Walter Herman Maria Louis;  
Janssens, Frans Edward; Kennis, Ludo Edmond Josephine (Janssen  
Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 945011 A1 19990910, 30  
PP-  
CN, DESIGNATED STATES: W AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,  
CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LD, LE, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,  
US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KE, MD, RU, TJ, TM; RW: AT, BE, BF,  
BJ, CF, CG, CH, CI, CM, CY, CZ, DE, DK, EG, FI, FG, GA, GD, GE, IL, IT, JP,  
KE, ML, MR, ME, NL, ET, SN, TH, TG, TN, TZ, (English), CODEN: FUXKX2.  
APPLICATION: WO 1999-FP1308 19990226. PRIORITY: EP 1998-200700 19980306.

GT



L5 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN(C)C(=O)C(Ph)(Ph)CCN1CCN(C1)Nc2ccc3c(c2)c(c[nH]3)C(=N)C(F)(F)FCC(=O)N1CCCCC1C2=CC=C(C=C2)C(F)(F)FCN(C)C(=O)C(Ph)CCN1CCc2ccccc2CC1CN(C)C(=O)C(=O)C(c1ccccc1)CCN2CCCCC2C(=O)Nc3ccccc3

15 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 1998:568820 Document No. 129:202941 Original Reference No.  
 129:41223a, 41226a  
 Preparation of amide derivatives as selective neuropeptide Y receptor  
 antagonists. Connell, Richard D.; Lease, Timothy G.; Ladouceur, Gaetan  
 H.; Osterhout, Martin H. (Bayer Corporation, USA). PCT Int. Appl. Wo  
 9839557-1 19980820, 66 pp. DESIGNATED STATES: VE: AL, AM, AT, AU, AZ,  
 BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH,  
 GM, GW, HN, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
 SL, TJ, TM, TR, TT, UA, UG, UZ, VN, ZM, ZW, AZ, BY, BG, BZ, CA, CU,  
 CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, GT, HK, HU, IL, IN, JP, KE,  
 KG, KR, KZ, LC, LK, LR, LS, LT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD,  
 TG. (English).  
 CODEN: PIXPKD. APPLICATION: WO 1998:US2121 19980205. PRIORITY: US  
 1997-800482 19970214.

```

pre      Thus, reaction of N-(4-cyclohexylphenyl)-2-bromacetamide with
the      4-benzyl-4-hydroxypiperidine in the presence of K2CO3 in DMSO afforded
IT       title compound II which showed IC50 of 0.15 nM against hNPY5.
         212052-34-1P 212052-63-6P
         RL: BAC (Biological activity or effector, except adverse); BSU
         (Biological
         study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
         BIOL (Biological study); PREP (Preparation); USES (Uses)
         (preparation of amide derivs. as selective neuropeptide Y receptor
         antagonists)
RN       212052-34-1 CAPLUS
CN       1-Epipiperidine, 4- (4-aminocarbonyl)-N-(4-cyclohexylphenyl)-4-
         [phenylamino]- (JCA INDEX NAME)

```




RN 212052-63-6 CAPLUS  
CN 1-Piperidineacetamide, 4-(aminocarbonyl)-N-(4-benzoylphenyl)-4-(phenylamino)- (CA INDEX NAME)




10565979.trn

L5 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
1996:718222 Document No. 126:8132 Original Reference No. 126:1811a,1814a  
Preparation of arylglycinamide derivatives as tachykinin antagonists..  
Schmorrenberg, Gerd; Dollinger, Horst; Esser, Franz; Briem, Hans; Jung,  
Birgit; Speck, Georg (Boehringer Ingelheim Kg, Germany). Ger. Offen. DE  
19519245 A1 19961017, 29 pp. (German). CODEN: GWXXBX. APPLICATION: DE  
1995-19519245 19950525. PRIORITY: DE 1995-19514112 19950414.

GI



AB R1R2NCR3ArCONR4R5 [Ar = (substituted) Ph, naphthyl; R1R2N = Q1; X = O,  
N(CH2)nR6, CR7R8; n = 0-2; R6 = alkyl, (substituted) Ph, naphthyl; R7 =

= H when R3 = (substituted) Ph; R7 = morpholinyl, piperidinyl,  
pyrrolidinyl, 2-pyridinylamino, Ph, PhCONH, etc; R8 = H, CONH2, NMeAc,  
NMeAc; R7R8 = Q2; R3 = H, alkyl, (substituted) Ph; R4 = (substituted)  
phenylalkyl, naphthylalkyl; R5 = H, alkyl, cycloalkyl, CH2OH], were

prepared

Thus, title compound (I) inhibited binding of 125I-labeled substance P to  
NK1 receptors with IC50 = 1.4 nM.

IT 183732-12-9P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of arylglycinamides as tachykinin antagonists)

RN 183732-12-9 CAPLUS

CN 1-Piperidineacetamide, 4-(benzoylphenylamino)-N-[(3,5-  
bis(trifluoromethyl)phenyl)methyl]- $\alpha$ -phenyl- (CA INDEX NAME)

L5 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

1996:609954 Document No. 125:247623 Original Reference No. 125:46285a


Preparation of 5-[(4-substituted)piperidin-1-yl]-3-arylpentanoic  
acid-derivative tachykinin receptor antagonists. Bernstein, Peter  
Robert;

Dembofsky, Bruce Thomas; Jacobs, Robert Toms (Zeneca Limited, UK). PCT  
Int. Appl. WO 9624582 A1 19960815, 110 pp. DESIGNATED STATES: W: AL,

AM,

AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE,  
HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI; RW: AT, BE, BF, BJ, CF,  
CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE,  
NL, PT, SE, SN. (English). CODEN: PIXXD2. APPLICATION: WO 1996-GB259  
19960208. PRIORITY: GB 1995-2644 19950210.

GI



AB The title compds. (I; Q1-Q4 have the meanings given in the claims; \* = an  
optionally asym. center) [e.g.,  
N-benzyl-5-(4-hydroxy-4-phenylpiperidino)-


3-(3,4-dichlorophenyl)pentanamide; m.p. 64-67°] are nonpeptide  
antagonists of substance P and NKA (e.g., neurokinin NK1 and NK2  
receptors), useful for the treatment of asthma (no data), etc. (no data),  
are prepared

IT 181879-25-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(preparation of 5-[(4-substituted)piperidin-1-yl]-3-arylpentanoic  
acid-derivative tachykinin receptor antagonists)

RN 181879-25-4 CAPLUS

CN 1-Piperidinepentanamide,  $\beta$ -(3,4-dichlorophenyl)-N-[(2-  
methoxyphenyl)methyl]-N-methyl-4-[(1-oxopropyl)phenylamino]- (CA INDEX  
NAME)




10565979.trn

L5 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
1984;630558 Document No. 101:230558 Original Reference No.  
101:35017a,35020a

6-Aryl-4,5-dihydro-3(2H)-pyridazinone and their use. Roszy, Phillip A.;  
Thyes, Marco; Franke, Albrecht; Koenig, Horst; Lehmann, Hans Dieter;  
Gries, Josef; Friedrich, Ludwig; Lenke, Dieter (BASF A.-G., Fed. Rep.  
Ger.). Ger. Offen. DE 3302021 A1 19840726, 52 pp. (German). CODEN:  
GWXXBX. APPLICATION: DE 1983-3302021 19830122.

GI



AB Antihypertensive, blood platelet aggregation inhibiting, and stomach  
secretion inhibiting (no data) title compds. [I; R = (un)substituted  
amino, heterocyclyl;  $R^1$  = H, Me;  $R^2$  = H, alkyl;  $R^3$  = H;  $R^2R^3$  = alkylene;

n


= 0-3] (66 compds.) were prepared. Thus,  
(propionamidophenyl)pyridazinone II  
( $R^4$  = Cl) was heated 8 h at 80° in DMF with morpholine to give 82%  
II ( $R^4$  = morpholino).

IT 93278-02-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 93278-02-5 CAPLUS

CN 1-Piperidinepropanamide, 4-[(1-oxopropyl)phenylamino]-N-[4-(1,4,5,6-  
tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- (CA INDEX NAME)



10565979.trn

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 10:37:34 ON 08 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 5, 2008 (20081205/UP).

=>